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ABSTRACT 
HEPATITIS C TREATMENT: COMMUNITY-BASED, MULTIDISCIPLINARY 
APPROACH TO AND IMPROVE 
Hepatitis C is a major international health care dilemma, occurring frequently in 
populations who other health care Hepatitis C is the most 
common blood-borne infection and the ...... aUH,.r; cause liver disease the States 
(U.S.), causing 10,000 -12,000 deaths per year. According to the Centers for Disease 
Control and Prevention (2008), up to 3.9 million IJ'-'V'lJl'- are affected with the hepatitis C 
virus (HCV) within US. Estimates that 75% affected with HCV 
are unaware of diagnosis, and of those, only one in people are ATT", .. .,.rt 
treatment. Some researchers suggest that all residents born between 1946 and 1970 
be hepatitis C over a 5-year period. 
HCV carries an estimated financial burden of $10.7 billion nationally, and 
$377 million in Michigan Barriers to treatment include the lack of qualified 
healthcare providers and treatment programs; rigorous treatment regimens significant 
medication effects; psychosocial challenges include mental illness; addiction; 
ugnnatIzat],on; and " ..... '.Ull''''' .. ,..., coverage. The purpose of this project was 
improve access and care individuals hepatitis C an area. 
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populations 
1 
INTRODUCTION 
international dilemma and occurs frequently 
from other disparities. According to the ....;"""r.'~f"'""r~ for 
Disease and Prevention (CDC, 2008), to million people are affected with 
C within the States (US) number rises to 1 
million world-wide (World Health Organization [WHO], 12). Hepatitis Cis 
"'_U.'-'H,'f'> cause of liver is the one reason for liver transplantation, 
(NIH, 2002). Hepatitis C is the most according to the National Institutes 
common blood-borne infection in US and it with it an financial 
hn".rtpn of 10.7 billion nationally (Wong, McQuillan, McHutchison, & Poynard, 2000) 
377 million Michigan alone (Michigan 
2010). 
Community 
Wong et al. (2000) forecasted 
between 2010 and 2019. Their ...... ""''''''1'. 
greatest burden HCV would occur 
and Nutrition 
likely become a 
McGarry et (2011) 
1 and 1970 over a 
were on data trends in the National 
<AUU.HVH Survey III 1998). estimates 
age-based the HCV are <>rtr'r\1'~'rt 
for hepatitis C for US residents born between 
period. Among 102 million 40 to 64 
1 
as as 1.3 million are infected with 
... "..,'ll",,",, this population could current 
__ .. , ....... would identify only 427,000. This means 742,000 
be diagnosed and treated if current 
cost saving of age-based screening occurs with early of 
advance 
liver 
to reduce the numbers of individuals progressing to 
transplantation, or death. 
national guidelines exist for the treatment of the 
individuals .. """.,,"" 
and established treatment 
therapy. Estimates in the US today 
C are offered or 
treatment, those with 
probability of worsening liver disease, and 
systems are not meeting the of 
McIntyre, McLeod, Nathwani, & Dillon, 10). 
to involve an integrated approach to care with 
collaborating to address the many n<lTT1P1r<: ,,,,,,,v,,",,,,,,,",,,, 
treatment. Extension for Community Healthcare Outcomes 
...... r'rr .. ," ........ ae'"elc)ne:a by the University of New Mexico Health 
of 
of 
(UNM 
was designed to specifically address the needs fJ' .... I"'''.'' with 
is a lack of qualified providers to treatment 
reg,lmlens (Arora et 20 I 0). This program was developed 
outcomes with hepatitis C and is now 
2 
programs to manage a variety 
involves professionals from a 
coordinate recommendations prior to 
messt:s (Arora et al.). This approach to care 
disciplines who collaborate and 
during hepatitis treatment. 
Project 
Improving healthcare outcomes can enhanced by applying an 
approach to current gaps in .... r"f'TU'A project, the approach a 
on specific healthcare initiatives related to 
became the foundation for clinical 
review and critical synthesis 
hepatitis C. The critique of this 
guideline development and ...... U.HF," (Coopey et al., 2006). 
In an effort to improve care 
community in West Michigan and 
lTr1nrcn,p' access to HCV treatment were 
approach. A five-step model 
following: clear identification of the 
with hepatitis C in a shoreline 
rural 
by applying an evidence-based 
...... r''''''''T development and included 
systematic retrieval of existing 
to 
critical appraisal of the evidence; application of results, and evaluation of the 
innovation (Johnston & Fineout-Overholt, The goal of this project was to ' ....... · ...... r'''''' 
programming that could aa(lre~:;s 
individuals diagnosed with hepatitis 
access to HCV treatment by ..... ",,,,rj 
multitude of health 
Ultimately, a multidisciplinary, ~,-, •• .uu.~U 
Chronic Care Model (CCM) was 
project. This model seeks to improve 
collaborative partnerships (CCM, 2010). 
3 
treatment clinic was developed 
as conceptual framework to 
management with cohesive and 
model offers strategies to manage chronic 
illness by J.'V .. ' ...... " ........ on 
resources and policies; 
t<>r'y .. t~.rl on six specific components: 
organizations; self-management support; 
system design; decision support; and clinical information systems. In "''''''«,!,;' 
related needs of patients 
but specific clinic 
1"1 .. ",<>1"11"." C, the chronic care model was fully Impleme:nt(~C1 
and decision 
on the components of selt-ITlanlaglement "'""'''''Art 
in an ..... '''H!-'. rr,nnn!? long-term HCV outcomes. 
Background 
is and individuals C can 
remain asymptomatic of time, making accurate rates 
difficult to estimate. rates currently exist, reported numbers not 
reflect incarcerated, mentally ill, or homeless populations. HCV exposure results in a 
chronic infection in approximately 85% of individuals, and of those, 10-20% will 
cirrhosis (Wise, Bialek, 
increases the for 
& Sorvillo, 2008). The presence of chronic 
"'''-'OJ''''''' hepatocellular carcinoma and the subsequent 
liver transplantation Wilhardt, Morreale, 2002). As a health 
hepatitis C accounts for 8,000-10,000 deaths per (Geppert & 
Sonnad, & 
Cis a 
the highest prevalence rates in 
Floreani, 2008). Individuals 
highest risk due to the prevalence 
persons affected with the HCV 
(IVDU) practices (Paterson, nalCK11nurlO 
transmitted infection (Flamm, 2003) 
of age (Baldo, Baldovin, Trivello, & 
disadvantaged popUlations are at the 
.. "",rr. .. " in these populations. The majority of 
4 
non-sterile intravenous drug use 
& Vim, 2007). As many as 95% 
drug users 
20-30% 
HCV virology (Geppart & Arora, 
with mental UH • ...,"'''' are infected with 
It is 
which is 
significantly higher than rates in the genera] population of 1-2 % (Rifai, Moles, & 
Short, 2006). Other populations at risk for the HCV the incarcerated where 27-
54% with (Pradhan, 
2005); of homeless nPT""" (Nyamathi et al., and 2.6% 
approximate 5.6 million military veterans (Veterans Health Administration [VHA], 
2010). 
identifYing '-''''''-''OJ'''' at for HCV InlleCl:IOn reqUIres knowledge of 
routes of transmission, some which are not to risky behaviors. For example, 
individuals were at increased of hepatitis C '-'i\.~JV""UJ, 
routine HCV sCfleenmg was initiated 
during blood 
blood products. 
or equipment 
to 1991 
healthcare 
risk for 
exposed to contaminated 
the HCV. risk behaviors 
person; sharing personal hygiene items such as razors 
body 
although 
using non-sterile practices; sharing 
""".vufrom 
Elements Hepatitis C Virus Treatment 
tte1patms C was first ript,"'l'N>ri in 1989 (Choo, 
1989). is diagnosed 
at increased 
having sex with an infected 
tooth brushes; tatltoomg or 
drug ~UJ, ,,~,U,-,. or, 
to child (Baldo et 2008). 
Weiner, Overby, 
(RNA) 
can blood post-exposure anywhere from 1 180 days after transmission (AI-
Saden, McPartlin, Daly-Gawenda, Connor, & Zelenka, 1999). Symptoms in 10-
5 
1 acute hepatitis C mIeellorlS include malaise, ",nt"w""", jaundice, urticaria, 
explain 
& 
in more 
elevated liver pn~7'rn1p", (AI-Saden et at) 
C viral genome is not found consistently or semen which 
infrequent transmission disease in close or contacts (Fried, Shindo, 
The HCV can be as one of six and further classified 
subclasses (CDC, Genotype 1 accounts of all 
mrectloJ:lS in the United is associated with rates to 
treatment 2002). Genotypes 2 3 are more frequently to IVDU (Hamlyn, 
2005). While some individuals will spontaneously clear the virus, it is estimated 
asymptomatic that up to of people will develop chronic HCV which is O'f'I1If'T::l 
1999). 
primary goal ofHCV treatment is sustained 
reduction the progression to hepatic fibrosis, minimization 
ViruS, 
development of 
de(;OIlnm~nsated cirrhosis, and lastly, reduction ofthe incidence carcinoma of the liver 
(Santos, 
from 6 
Digestive 
ForaH 
protease 
& Dieterich, 2005). According to ~'u,~ .. ., .... guidelines, 
which can vary dominant aelemrunmg in the course 
to more than a (Ghany, Strader, Thomas, 2009; National 
.""' ... ...,"',, Information Clearinghouse [NDDIC], 2010; Woods & Herrera, 2002). 
AT""'''''' therapy for hepatitis C involves daily oral .... v,J ... "" of ribavirin and 
a pegylated 
with genotype 1, 
addition, new treatment 
as triple therapy including 
are 
interferon, 
direct-acting antiviral (DAA) therapy with Boceprevir or Telaprevir. These 
have markedly improved sustained viral responses (Ghany, Nelson, 
6 
Strader, Thomas, 2011). Regardless treatment 
management and monitoring required by the provider and considerable 
accountabili ty 
intensive work 
accurate dosing and surveillance. Non-optimal success rates 
providers are two ug~~esltlorls provided by Brok, Gluud, 
Gluud (2010) as to reason only 25% LlvV'LI<v are being r' .. t1'a. ... ~'rl 
treatment. 
Population of 
The community of interest for this project is located along the shoreline of 
western Michigan. It is an area characterized by eC()flC)mIIC depression, high 
unemployment 
the Community "''',.,,''''' ..... 
population 
community at the 
racial backgrounds. 
the largest cohort is 
than 
populations at risk for access. According to 
(cru) of a area, the 
was 172,188 in 2010 (cru, 10). Of those living in 
77% were white, 14% Black, and remaining were of various 
and female residents were With regard to 
olds (21.9%) with cohort 5-17 year olds 
of the community residents are I;;;UIc!I;;;(l.LI;;;U beyond high schooL (20.7%). 
With an Ir"11rY1Plr'1T rate of 17.6%, nearly 12% poverty. 
community an setting and all this area are rurally 
designated. It is well that those residents living areas face 
Spencer, & extraordinary challenges accessing healthcare (Goins, Williams, 
Solovieva ,2005). In approximately 1.8 million (1 people live in 
designated out of the 140 hospitals Michigan, of them are 
located in rural areas rl..;).:)1.;)lau,_v Center, 201 
7 
..... P.,..,P.·" 2006 and 2011, individuals hepatitis C 
an additional 
lacking confirmatory testing) 
Lln,'''<'<''1'' cases (those with HCV antibody but 
to the Michigan ....,"',,, ..... ,'" Surveillance System, 
201 
2157 to 
estimated prevalence of C for the community interest ranges from 
(L. Stegmier, personal communication, July 1 1). These numbers are 
estimates as 11) reported overall 
been infected Using those same vU.l"' .. JlU.LJ.VU.:>. two of the 
counties north of the community of i"t,,,,,.,,,,,,t have the following rates of 
hepatitis County A, 342 to 430; 640 to 760 (L. personal 
communication, July 12,2011). 
on the C 
compared to those confirmed cases 1""'~'r."T"''' roughly one third believed to have 
hepatitis C been diagnosed. ""',.,""',,,"'" the issue of HCV treatment is heightened 
providers and concerns by primary care when r-A1,.."t .. .,,, ... 1",, are imposed by "V"','vlU'U 
n .. ..,,".f1,"' .. '" u",\,.,au;~", of the perceived appropriate local HCV care. 
concern, ~ .. , .... "'Vu to 
addressing this 
from the 
local hospital and federally "''''1''',,"''' healthcare agencies. 
Barriers to HeV Diagnosis and Treatment Access 
and Access to Care 
of health care 
western Michigan that contribute to 
care individuals who 
access to adequate care. 
for residents 
from the HCV in 
8 
shoreline of 
to 
community is limited 
Goins et al. (2005) describe the perceived barriers to healthcare access among 
mral older adults. They depict barriers to healthcare access in three ways: entry, 
stmctural, or cultural. The investigators report financial issues as the leading entry barrier 
to healthcare access and cite issues with individuals who are uninsured, underinsured, or 
lack prescription coverage. Stmctural concerns refer to lack of qualified specialists or 
testing facilities in rural communities requiring most residents to travel for specialty care. 
For those living in the community of interest, limitations to care are posed by existing 
local medical specialists. As a result, people with hepatitis C lack consistency in follow 
up. Lastly, cultural practices and norms among ethnic minority populations or groups 
may lead to an undemse of services or have additional challenges associated with 
language barriers. 
Goins et al. (2005) also reported on five common themes that emerged when 
assessing access needs, specifically those in mral areas: transportation difficulties; 
limited healthcare supply; lack of quality healthcare; social isolation; and financial 
constraints. The challenges in accessing adequate healthcare, specifically for individuals 
with hepatitis C treatment living in rural areas, was one of the main driving forces in 
establishing a dedicated hepatitis C treatment clinic. Because transportation challenges 
were the highest reported barrier and were especially aggravated by poor weather and 
road conditions, the location of the shoreline clinic intentionally reduces the travel for 
these patients. Next, the limited health care supply refers to the lack of qualified 
providers practicing in rural communities. Additionally, Goins et al. suggested that when 
there is limited availability of diagnostic testing coupled with provider disinterest, illness 
management is hindered. The fourth category of barriers describes the social isolation 
9 
by adults. This may lead to a lack of understanding of healthcare 
services at the local level. Finally, financial constraints include travel eXt)en15es. 
diagnostic testing, prescription medications. concerns are exponentially 
heightened individuals are either underinsured or uninsured. 
Geppart and (2005) provide opinion on five clinical-ethical 
arguments surrounding the availability HCV treatment. investigators reported 
justice, compliance, cost-effectiveness, balance of risk and benefit, and discrimination as 
that limit the access to treatment. As such, these authors 
be a professional social obligation to nn-th<'" explore clinical-ethical arguments in 
vulnerable populations. 
Stigmatization as a Barrier to HeV Treatment 
Stigma is a complex social phenomenon which is subjective and variable (Butt, 
2008). has associated with many chronic infectious diseases such as 
leprosy, tuberculosis, and human immunodeficiency virus (HI V) (Butt), yet is little 
exploration into 
hepatitis C ~('('·l'\r,"1. 
social and psychological implications of being diagnosed with 
to Hopwood and Southgate (2003). Discrimination, fear of 
transmission, and self-loathing are only a few of 
with HCV (Hopwood & Southgate). with 
• .,,,,,v,,,,,, their diagnosis avoid healthcare fail to 
infectious UAY'''''u.~...,,,, 
fear of ridicule 
discrimination, have strained interpersonal relationships (Paterson et a1., 2007). 
who have through IVDU are especially vulnerable as the 
association of drug use and infection is viewed as a self-inflicted "">AUHAV .. caused 
10 
irresponsible behaviors (Paterson et al.). Individuals may as having 
a "dirty disease" 
C stigma was examined an of 30 studies completed over a 12 
year time frame (Butt, 2008). Stigma was most frequently, but not perceived exclusively, 
as a negative .... Uti!"' ... ,\.! of and in a variety Ina by 
Moore, and Bradley (2007), stigma was reported to occur most often in 
home setting. suggest that over time, ..,HI.,"A"" can result in 
V"~,,'':'''VU''''l':> or family can cause a cascading effect a 
This maybe 
vulnerable to discrimination, 
& Treloar, 2006). For some, disclosure issues when 
individuals share their HCV diagnosis with others out sense of VUJ:';<HIVH to protect 
them. This 
against 
be followed by same ridiculing or discriminating 
leGJ;errtent of the stigmatization by health prc,reSSIOnal IS 
imperative for improved quality of life for per'S0I1S with the HCV. Interventions ('u'.<trt>,-j 
toward reversing social perception of infectious diseases can be initiated through changes 
in binary thinking, according to and Treloar (2006). The ~~UAV"''> believe is 
accomplished through education on what am)eaJrs to be consequences by 
Concepts of" health/illness ," "clean/contaminated," 
"well/sick," "good/bad," and "before/after infection" can all be in such a 
that a more outlook. and Treloar further described the 
advanced practice nurse (APN) as a qualified professional to cOlirlsel individuals 
11 
hepatitis C by first establishing a relationship. Through individual or 
",","·""J'11". the APN can give accurate information on transmission risks, AHUAU.'l>;'"' treatment 
options, advocate for with the Their u ......... "'''' suggest improved 
UVL ... ,,'U for persons with hepatitis C can ultimately reduce their vulnerability to 
stigmatization. 
In hepatitis C is an infectious it can be through 
innocent means, although most n"tPf'l'U\" continue to occur by IVDU (CDC, 11). 
psychological, social, and emotional responses can occur in those who are 
Olagnose:Q with the HCV. Persons with hepatitis C are vulnerable to stigmatization 
discrimination by healthcare professionals, family, friends, and co-workers. 
QuaJity of andHCV 
Quality of indicators are infrequently .. A,.\,y,"t",rI in the In ..... ".r''''n with 
hepatitis C (Zickmund, Ho, Masahiro, Ippolito, & LaBrecque, 2003). Reported studies 
focus on treatment and but few report interpersonal 
challenges faced by those infected (Cotler et 2000). Published findings on stigma and 
chronic hepatitis C indicate a negative on health outcomes and reduced quality 
life McGuinness, The decision to treat h"' ... .,i-·'h'" C forces 
to between negative of treatment (medication effects 
and rigorous treatment and long-term gains of eradicating the 
(Schackman, Teixeira, Weitzman, Mushlin, & Jacobson, 2008). 
treatment mild flu-like symptoms, nausea, itching, headache, irritability, 
alopecia (Holcomb, 2008). Cotler et describe how medication effects can 
significantly the person's ability to function in the work environment or within the 
12 
home. Financial may be compromised because of the potential limited capacity 
to fulfill employment responsibilities. treatment can improved 
::Sch;acJanan et al.). quality of life 
Hepatitis C St'l1"PI"n 
For the decades, Healthy ,-"'''''''''' has identified the 
detection and treatment the HCV. Healthy 2020 released objective to 
increase the percentage of people aware chronic hepatitis C mllectlon (Healthy 
2020). In this initiative, attending Digestive 
Disease week et aI., 2011) a one-time birth-cohort screening for 
baby boomers, those born in the US between 1946 and 1964 over a ,-""'''' .. period. 
Because individuals 
diagnosed with 
the numbers 
hepatitis C typically 
20 years or more. 
aware they 
according to Rein et (2012). 
Leverence, et (2009) examined 
no symptoms, not be 
~~t"h~·~.~·~ a~b!'e-Da~,eo screening will 
HCV and will 
screemng nralcw:::es prImary care 
providers (PCPs) a wide variety of contradictions 
scientific national PCPs reported as being and important 
(68%) but neglected to obtain necessary information regarding risk behaviors ofIVDU 
(54%) or exposure from previous blood (28%). study heightened 
awareness of 1"1l""P<;I'''Pf'1 education 
consistencies in national guidelines as UH .. • ..... U.;.u 
study were supported a qualitative study by 
investigators developed a survey to review the 
13 
to improve care. 
et a1. (2001). In 
screening practices of 
in this 
study, 
within 
the Primary Care Network (PRIME Net), on medically lni1,pr<,PnlPi1 
about HCV risk factors. 
galtek1ee[len;;" who are eSS,ell1Ual 
communities. Only 59% PCPs in the study rpr\"rtpr! 
This raises concern for underdiagnosis of the HCV 
early diagnosis and treatment. In this study, 
patients. Participants 
of practice 
study practiced in rural, 
behaviors 
and experience with 
urban communities. 
No significant were found in their attitudes Tr"'J<n'n and actual 
screening practices among 
As discussions 
know that currently no 
hepatitis B are 
four provider networks "'''~~''''''P'~!''''f->' 
prevention for 
(CDC, 2011). 
individuals with hp?,,,n:n C 
'"'v ..... ,: ....... it is important to 
hepatitis and 
for those with 
known liver disease (Wilkins, Malcolm, Raina, & Schade, 2010). 
Populations at Risk 
The highest rates B"IJ ...... ~ C are reported in np,.""n psychiatric illness 
and those with addictions to UlvVl1'Vl and/or IV drugs & 2008). At 
same time, individuals in populations are most common group 
deemed ineligible treatment in spite of the fact they most likely to acquire the 
disease. Abou-Saleh and (2008) suggest the dilemma HCV outcomes 
is daunting because 
population and the limited 
Psychiatric Illness 
Individuals with 
populations who lack 
-~U"'b prevalence of hepatitis C arrlong this at-risk 
resources available to 
VB ...... AV illnesses continue to be one the most vulnerable 
healthcare. This is especially true those with hepatitis 
14 
C and mental 
also have 
u ....... 'a "",.., it is that 20-30% those who 'U"""H~ illness 
treating with mental is of national 
to the financial burden societal obligation to reduce healthcare 
inequalities. Healthcare disparities occur when ... ". •. ,"' .... ", with mental UUA, .... .,., attempt to 
navigate numerous barriers access to care. may stigmatization 
providers of care, of access to " .. r"f1r'~" and social support, and lack finances 
for services or recommended ph,arrna(~eu 
Unfortunately healthcare ,",,,<.Lu,",u by the ill are sometimes 
in ignorance and apathy by the healthcare industry. The magnitude Issue 
prompted Institute of lVle:Qlc:me (10M) to lU"'U. ...... a committee to address healthcare 
disparities for those with psychiatric The committee on Crossing the 
chasm: Adaptation to mental health and addictive disorders was developed in part to 
"."",.F. .... " and understand gap between who could healthcare 
who do .. """""n""" healthcare et al., 2007). In this report, the ... "'"I-'UJ.h' .... between 
these two groups is described. With this understanding, the committee was charged with 
...... ,J:\.Ul'f::, recommendations to reduce these disparities. The orc,oo:seo framework to 
improve healthcare delivery was focused on six important criteria: natlerLt-c:en1ten!O 
effectiveness, equity, timely, and efficiency (Pincus et al.). 
Treatment and Psychiatric Inness 
The Institutes suggest that treatment considered for 
with psychiatric on a cruie-[)V-( basis (Mistler et 2006) UI..'I..'(lU;:)1..' 
profound risks associated with treatment. Psychiatric co-morbidities include a 
diagnosis depression, ",,,, .. cnn disorders, disorders, anxiety, post-
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traumatic stress ,,,,,,rflr'r or other mental Rifai, & Van 
Linden, 2005). Neuropsychiatric side PTT'>!'T'" are well known with interferon 
(Strinko, Bisceglie, Hoffman, 2004). One third of persons receiving 
treatment will exhibit neuropsychiatric side pH-""t", and individuals 
-0,,----'0 with mental 
illness can devastating C0I1Se'Ql & Gabriel, 2003). IS 
the most common reported neuropsychiatric effect with "panic anxiety, 
emotional lability, irritability, anger, QQ]:es~Sloln. hypomania and uu.;,,,,,,, confusion and 
disorientation" (Silverman, Kim, Freudenreich, 2010, p. 2). a cross sectional study 
by ZicknlUnd et al. (2006), physical, mental, social complaints of patients undergoing 
treatment helped to practice needs for providers. In Zickmund et 's 
study, physical side were by 80% the participants while 38% rpnnrt.>fi 
depressive feelings. Suicide and death have been reported in persons unrecognized 
untreated psychiatric effects (Crone & Gabriel). 
Research on the of ,nTprTprr." usually exclude individuals with 
psychiatric .HU, ........ based on physician reports of depression and not on a professional 
psychiatric assessment (Mistler et 2006). In in a study by Alfandre, Gardenier, 
Federman, and McGinn (2009), over 75% of persons with documented C, who 
were medically eligible for tre~ltrnent, did not therapy initiated. Psychiatric 
illness was reported as a reason why to initiate treatment was so 
Individuals in population may have lower levels of health and lack 
understanding of the and modes transmission (Alfandre et al.). Lack of 
insurance, low 
to successful 
of literacy, and limited access to serve as further n<>TTlP-r" 
treatment (Gardenier, Neushotz, O'Connor-Moore, 2007). Crone 
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Gabriel (2003) reported that of life .u .... "', .. v,'''' are impaired for persons 
chronic C are especially significant for with Social 
",n~l .. ,,·n interpersonal relationships, and Sm;lOeC()llCm constraints in 
with psychiatric illnesses lead to non-compliance with appointments, testing, 
and psychiatric medication which contribute to further ineligibility HCV treatment. 
In Weiss Morgello (2009) ",,,..-uP,, results specialty 
providers who service individuals with 
the most common effect HCV treatment 
illness and the HCV. Depression was 
.... ""."'uu'vu. However, the majority of 
providers acknowledged that treatment needed to 
because worsening symptoms. this study, 65% 
than 20% the 
'''''.IT'''''''T<' with psychiatric UH1.'-'''''' 
achieved a 20-60% sustained viral response from treatment which is the 
treatment success for DeI'SOIlS without The investigators concluded that 
stabilization of psychiatric ~.u_~"~ is incredibly important prior to starting therapy 
in order to reduce the neuropsychiatric effects (Weiss & Morgel1o). 
et al. (2006) and Quelhas and (2009) completed systematic reviews 
examining HCV treatment individuals with mental illness. 2006 explored 
research studies as compared to 2009 which investigated 13 studies. Both 
systematic reviews that patients with psychiatric illnesses are commonly 
excluded from clinical research on hepatitis C. of the included the 
Mistler et al. report, concluded that majority of individuals completed therapy 
low drop-out adhered to treatment guidelines, Ide-ettects when 
<Yln-""",,,,·,,,,," psychiatric management close monitoring was used. The bulk ofthe 
reviewed were from small studies and overall conclusions support 
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outcomes in 
treating patients with mental illness and hepatitis C. suggests that controversy and 
are common over whether or not ... ", ..... .u illness should be an absolute 
for HCV treatment. 
HeV Treatment and Substance Abuse 
Historically, substance abusers or addicted to either alcohol or 
deemed for HCV treatment based on factors (lohn-Bastiste et aI., 
2009). may include lack readiness, perceptions that harms of treatment outweigh 
belletlts. poor compliance, treating the has low when compared to other 
health concerns. (lohn-Bastiste et Because IVDU '"'''', ...... ,''' as the cr .. ""<>t",,,,t risk 
m new virus (Armstrong et aI., 2006), new treatment need to be 
considered for these ,,u-, • .,'" populations. challenges further 
because are greater numbers IVDU among individuals who are for HIV, 
which accelerates the progression ofHCV-related disease (Bica et aI., 2001). In fact, 
authors the HCVas primary cause death 
in this HIV -seropositive population. One strategy reported in the literature has been a 
comprehensive u,","'",,,,", eXlch,mg;e program implemented in New York that has 
substantially that (Birkhead et 2007). 
been closely ".U\u ..... u as it pertains to epidemiological 
histological m(]tlc~ltOI:S associated with Hepatitis C infection is foood 
nearly 40% of ..... "' •• '-' ... .., with alcoholic liver disease and leads to rapid veJ(mITLent of 
in patients admitting to ingesting >40gms per day alcohol (Degos, 1999). 
,,"'UU.,'" there is an impaired respOItlse to interferon in individuals who use alcohol, 
greater morbidity and mortality contribute to poor outcomes (Blackard, 
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Bordoni, 
Shennan, & ....."u~.n!'" 2004). a result, there is an extraordinary for 
programming focused primarily on individuals with n",,,'n'>I 
UU\..u ... 'k ... U to alcohol that also c. 
Treatment Guidelines and a Multidisciplinary Approach 
et (2009,2011) authored an pvtp""""P on guidelines for 
diagnosis and treatment of hepatitis C. 
American Association for the Study 
published guidelines were approved by 
'-' • ..,"'.....,,~.., (AASLD), the Infectious Lfl;::'I;,;Q.;::'\;:;;::' 
America, the ...... 'v", .... '" >JV'Io#l .... y of Gastroenterology. clearly 
states that "interferon and ribavirin can be safely administered provided there is 
comprehensive Df{:tre~atrnellt psychiatric assessment, a benefit analysis is conducted, 
and are provisions for on-going follow up of symptoms during 
antiviral therapy by a multidisciplinary team" (Ghany et al., 1362). National 
Institutes of Health suggests persons with substance abuse and/or mental 
(Mistler et aI., 2006). The complexity of 
individuals with hepatitis C and co-morbidities may input 
variety The of a multidisciplinary 
at annual r>r .... LlJLJlJ 
be 
approach in 
(2011) showing 
C was presented 
nrrn,p'rl compliance, lower reSDOIlse. and 
increased quality-adjusted years (Garcyia-Retorillo, 2011). 
In 
Relevance for Nursing 
Advanced practice nurses (APNs) registered nurses (RNs) playa role 
an even rrr"·,,,t,,·r role care individuals with hepatitis C and are uv.·..>"u to 
future (Olson & Jacobson, 2011). Development and implementation most models 
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care for individuals with hepatitis C involve nurse as a central caregiver. 
articles been published on the ",,,,,,,"'''-'.C' nurses in roles in the management 
individuals with HCV (Ahem, Cheng, 2010; & Ghalib, 
1999; Vu, & 2006; 2007; Ford 2007; 
Gardenier et al., 2007; & Timmins, 2009, 2010; Johnson & Holman-Speight, 
2005; Leone, 2002, Lewis, Allen, & Warr, 2010; Olson & Jacobson, 2011; Poll, 2007, 
2009; Robathan, & Vyas, 2008; and Van Zandt, D'Lugoff, & 2002). 
However, of the on benefits lead only 
to study specific improvements in care outcomes managed APNs (Ahem, 
Ehsani et aI., 2006; ,-,AV""UU 2008). Ahem 
nOlcators and treatment 
Timmins, 2009, 2010; and Shutt et 
outcomes quality of life (2006) studied 
outcomes between nurse practitioners physicians. While there were marginal 
differences in of indicators by provider groups, nurse overall 
provided as equal care when compared to DmrSlC:lans. and Timmins (2009, 2010) 
HCV treatment and whether patients studied most common side effect reported 
were satisfied with the care received by a nurse specialist practice. Fatigue, sleep 
lfo;anc:es. and 
high satisfaction 
study completed by 
loss were the reported side 
mana:gernel1t of complaints by 
stakeholders were 
and patients rated 
In a qualitative 
to 
nurses playa central role in 
crucial for education, side 
treatment. Those ''''''''''''''il''',", agreed nurses were 
UA""""",5"'.U"''', counseling, and treatment compliance 
when managing HCV treatment. Lastly, et a1. (2008) conducted a retrospective case 
looking at the addition of a clinical nurse specialist (CNS) impacted HCV 
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and treatment between 2003 and 2006 and f',UlnnlOl it to care 
provided in the years (1999-2003). reported that the rates of 
treatment doubled the with CNS with improved 
follow up including an increased number of ess.ell'nalliver biopsies performed. 
findings, United l\.lngclorn passed mandatory requirements that CNSs 
involved treating HCV (Shutt et al.). 
The remaining literature relative to nursing and HCV treatment focused on 
H.U",",UV1L'U):!. at fullest By definition, are 
registered nurses educated to function autonomously and collaboratively in an advanced 
and ext,en(led clinical role" '-''',",HI;;', 2010, p.6). According to several investigators, 
nurses can fiU to care providing 
management and support services (Clark & Ghalib, 1999; Johnson & Holman-Speight, 
2005; Van Zandt et al. 2002). an the Wald Model is community-based care 
by nurses for who are economically pr",p'n/Pn (Van 
et al.). model care on identifYing the to accessing care 
these barriers by evaluating community resources, improving health education, 
advocating patients, involving families. Conclusions model "'U~~l"."''''' that 
care working collaboration with a HCV treatment centers could 
access to h""r·~ ... " by reducing the of side lan:lgemeltlt with follow 
up. 
Poll (2007, 2009) the important role of the community nurse in the 
prevention, diagnosis, management of individuals with hPr'lOlT"T, 
nurses the lead role in educating on transmission 
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of the 
this study, 
and identifYing 
persons at highest Improved scr'ee1nmig protocols in diagnosing crrl' .. ,1".,1" 
numbers ""P7',;>£",,"" with the HCV who otherwise remained undiagnosed. If 
eligible treatment, a clinical nurse specialist manages medication dosages and side 
effects, laboratory monitoring, supportive care for patients 
completion ofHCV treatment and between SU(~CeSSI 
effect management was clarified in a study by (2002). Side "' ...... "" ... " include muscle 
flu-like symptoms, fatigue, sleeplessness, loss libido, nutrition concerns, 
L"'""'.AUV."",", (Leone). U", ... a.l.l"'" of the profound side ",1"1".>('1"" compliance with treatment 
regimens is difficult when treatment courses from 24-48 
remaining studies describe role of nurses in managing hepatitis C in 
difficult populations (Fahey, 2007; Ford & Cheong-Lee, 2007; et 2007; 
et aI., 2010). A case study reported by Gardenier et al. described use ofa 
medical/psychiatric with nurse practitioners. Historically, 
individuals with active substance use and psychiatric comorbidities have been ineligible 
HCV treatment. 
'U~"Uf"'" suggest 
study sought to remove those restrictions on eligibility. 
use of case management can barriers to HCV 
treatment. Similarly, a model of care involving the addition of a hepatitis clinical 
(2007). nurse specialist on a drug and alcohol team was by 
model, education and risk assessment care occurred in conjunction with drug and alcohol 
support groups. This model also includes nurses performing basic diagnostic testing 
Ford and ...... ll .... VIJLlo'.-l...,"'''' (2007) reiterated the need hepatology nurses to have a 
central managing HCV treatment. establishment of the Canadian Association 
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of Hepatology Nurses (CAHN) in has improved ability nurses to network and 
..... "',' ......... ,J the '-'H,"-VA,U":' challenges of managing HCV patients. Authors suggest 
H";U!"'!",HJ'!", n,:lt'I"ntc who have 
especially difficult to manage (Lewis et 
health problems and hepatitis C can be 
2010). In fact, persons with mental illness 
have the highest rates hepatitis C infection yet are least likely to access care. To 
Improve health outcomes in two United "'>.ULi".UVUL communities, 
development and implementation HCV protocols were initiated. involvement 
clinical nurse specialist improved care this especially at-risk population by 
case mana:gernellt monitoring. 
In sum, APNs exist in multiple and nurses are the most consistent 
healthcare V1V'.I. .... .;>.;>LVUUl in contact with patients. They are in an ideal position to advocate 
for improved access to HCV treatment and monitoring. Nurses can improve long-term 
health outcomes by reducing the health disparities among those most vulnerable. By 
F,YJ,"""'",""" or protocols HCV care, APNs are a In 
collaboration of care, education, counseling and support, and advocating for improved 
HCV progranlIning. 
Summary 
...... ("'v" ..... reviewed important factors pertaining to magnitude of 
state, local 
C treatment is and involves 
includes inadequate HCV screening 
of their hepatitis C diagnosis. For who 
dilemma. complexity of hepatitis 
to care. 
the majority of individuals unaware 
been diagnosed, there are limited 
numbers of qualified healthcare professionals and treatment programs available in the 
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community interest. further complicate the patients face rigorous eligibility 
criteria to treatment. illnesses, substance and co-
morbidities continue to be for individuals "'''''''A'-A'''F. HCY treatment. Additionally, 
social inadequate health care coverage, lack of support, lack of 
for those in surrounding rural areas are to HCY treatment. 
The dilemma of hepatitis C is on the rise and expected to be at its impact 
decade. quandary will heightened if healthcare providers adopt the 
birth-cohort boomers. and are 
charged with finding solutions to the challenges associated with screening treatment 
of hepatitis It is imperative innovative approaches to HCY care address 
limited access issues. 
In response to dilemma local, and national healthcare agencies, a 
hepatitis C was proposed and initiated as a doctor of nursing practice (DNP) 
project to improve the care for individuals with C the of west em 
Michigan. In order to provide an evidence-based approach to this project, the next 
VA ........ 'VA will present current literature on models of care to improve health 
outcomes individuals 
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of this 
2 
LITERATURE REVIEW 
is to review the to models of care 
for HCV community-based clinics. This review will encompass common barriers to 
treatment as they relate to models care identified in literature. To thoroughly 
explore current literature focusing on models of care for individual with the 
following y<nuv",,,,,",,,, were reviewed: CINAHL; Cochrane Reviews; Medline; PubMed; 
and PsycINFO. words or phrases this included hepatitis C; approach to 
treatment; multidisciplinary; integrated nursing; nurse practitioner; to 
treatment; collaboration; and In addition, lists of all 
literature were reviewed for potential inclusion. 
The absence of randomized controlled studies or comparative ofHCV 
of care was a notable m 
(Ho et 2008; et aI., 2006). 
aeI1ce;-D,lsea care for the 
treatment models, an ,>Mc&'t'n'<"\" was made to 
review and 
Due to the 
all 
two study 
in 
of consensus on HCV 
it",r"t,,..,, pertaining to 
current HCV models of care. To adequately develop a comprehensive treatment 
for persons with hepatitis investigating existing programs and 
L~ULvU<" that contributed to successful treatment was deemed 
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those 
ultimate 
goal of this was to allow the literature to guide and support what type 
would contribute the outcomes. of the early stage 
literature included that were and consensus as 
well as those reporting expert opinion. 
Three approaches to HCV care were identified in databases including 
multidisciplinary, integrated, care The ,",.n."0~,u ... literature was 
reviewed compared to obtain insight into the challenges associated with treating 
individuals with """",,,,1"11",<- literature reviewed was compared by 
and participants, inclusion and .... ".JIF,''', methods, theoretical TT"gTrlP'UTr'TV 
exclusion criteria, variables, scales and statistical study, and lastly, 
limitations and implications 
Multidisciplinary Models 
clinical practice. 
For the purpose of this review multidisciplinary refers to healthcare providers 
from different professions who work together to coUaboratively provide diagnoses, 
assessments treatment, within their scope and areas competence. 
contrast, interdisciplinary refers to the blending of two or more academic, scientific, or 
artistic disciplines (Merriam-Webster, 201 Thus, when describing models care for 
hepatitis C treatment, multidisciplinary care in this project constitutes the collaboration of 
health including care providers, infectious physicians, 
hepatologist/gastroenterologists, nurse practitioners, pharmacists, addiction 
psychiatric and social workers. This model was selected to <".tf, .. "",,:o common 
complexities seen in patients with hepatitis Because most patients with hepatitis C are 
from high-risk populations (C. Everett Koop Institute, 2012), 
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encounter significant 
m Instituting a multidisciplinary approach to HCV treatment ~ .... .., • .., ..... 
patients navigating barriers and allows healthcare professionals to provide an expert 
focus within their discipline. 
specific use or recommendations for mUltidisciplinary 
programming in treatment of hepatitis C (Arora et aI., 2011; Dolder et al. 2002; 
et aI., 2007; Grebley et al., 2010; Guadagnino et aI., 2007; Koff, 2001; Nazareth, 
Piercey, & Cheng, 2008; 2008; Gebremariam, & 
Schoenfeld,2002; Thiel, Anantharaju, & Creech, 2003). Four of the articles 
specifically on of studies employing a multidisciplinary !:lnr\rl"\<>l"n 
to H CV treatment. 
Arora et (2011) conducted a prospective cohort study comparing the outcomes 
hepatitis C treatment with individuals who were under treatment Extension 
for Community Health Outcomes (ECHO) treatment protocols in a university with 
treated by primary care providers 21 rural sites. treatment sites 
included in New Mexico. teleconferencing allowing 
a multidisciplinary team to collaborate with local care to 
provide treatment. Of 146 individuals treated for hepatitis C at the University of 
Mexico (UNM) HCV clinic, 84 (57.5%) achieved sustained viral compared to 
the 1 (58.2%) in the sites. Interestingly, reported rates of serious effects 
were in the UNM site (13.7%) compared to (6.9%) This study 
suggests benefits in treating individuals with hepatitis C typically underserved 
a multidisciplinary approach health technology. 
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""""'"6."""" et al. (2007) designed an observational, prospective study to explore 
the of a multidisciplinary approach in six infectious disease centers in 
collaboration with 11 Italian drug detoxification units (DDUs). partici pants 
underwent psychological ."''''Ul/; to identifY underlying mental Of the 53 subjects 
studied, 54.7% achieved ., ... .,.UU,l"'''' viral response. Team members were available for pre-
treatment counseling and during treatment evaluations and management. Weekly 
consultation at DDU allowed continuous ,.,..,,,.nn,n·, and encouragement from the 
team members. In this particular setting, all team members had an active role assisting 
patients. The relatively small sample size and type of drug treatment programming were 
recognized as limitations of this study. 
Grebley et al. (2007, 2010) most of their work on the support 
groups for individuals with hepatitis C receiving directly observed HCV therapy. In this 
study, weekly support groups served as a ...... 'vu.I.UU .... H for patients to education and 
social support. In the 2007 prospective study, 80 subjects were referred to support 
group over a period of 80 weeks. Of those, 18 patients who were illicit drug users 
enrolled in the study and HCV treatment. In total, 8 achieved end of treatment 
reSPOltlSe (HCV RNA <50mIIlU) despite some patients having to discontinue early. 
11U.I"/;" support the feasibility of HCV treatment IVDU 
by integrating a multidisciplinary approach and a support of 
this study is limited by the small study and lack of clarity in ,." ......... rt, 
The 0 study by Grebley et al. a approach and was an 
extension of 2007 study. In total, over a 3-year period (2005-2008), 204 individuals 
were referred to the weekly support group within the multidisciplinary program. Of the 
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109 for treatnlerlt, 57 ofthose referred received treatment suc:ces;sru There 
was a significant association between A ... ...,,"..., ... at the first four weeks of the support 
group and the """'.A..., .. ...., undergoing treatment for .,,'''.'''TlIT, these studies report 
success in individuals with current or former IVDU and hepatitis C by 
integrating a multidisciplinary care approach and a weekly support group. 
study by Dolder et al. (2002) reported outcomes veterans a San Diego 
Veterans Healthcare system. Their study examined access and cost ofHCV treatment by 
utilizing either a high intensity HCV treatment model involving a multidisciplinary team 
or a low (traditional) approach where 
reterred, and cases. The high intensity approach was found to treat a greater 
number of veterans more versus that of the low intensity model. cost 
found the treatment model totaled $33,318 compared to 
$38,082 for the low-intensity model. This study was one few to focus on financial 
burden of hepatitis The authors described the cost liver transplantation as 
exceealmg $240,000 with an additional cost burden of $23,488 per for 
follow up care. Updated by Foundation (ALF, 2007) for 
liver transplantation suggest a total cost $300,000 for hospitalization, physician fees, 
pre/post-operative testing. This study further describes the importance of 
pretreatment education and counseling as a means to increase completion rates. 
Implementing a multidisciplinary (high intensity) program increased the numbers of 
veterans who were able to successfully complete therapy. Conclusions reported in this 
study were based primarily on expert panel opinion estimated completion 
rates were on seen clinical trials. 
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cornerstone of a multidisciplinary approach is the participation 
of professionals from a """'PT" of specialty practices. To 
components of the model, studies were reviewed to compare 
me,Qlc:al specialty of the lead provider in the care of patients with C. Infectious 
provider three "LULH"''' (Grebley et "'lv1Ull.;) were vV1,'''''',!'''' the 
2007; Grebley et aI., 2010; Guadagnino et 2007), while hepatologist or liver 
specialists were considered lead provider in another studies (Dolder et al., 2002; 
2001; et al., 2008). Two referred to in both infectious 
disease and hepatology as the primary leader of the healthcare team (Arora et al.; 
2008). Additionally, three examined the benefits of the addiction specialists 
multidisciplinary for individuals undergoing HCV treatment a current or 
former history of IVDU (Grebley et al., 2007; Grebley et 201 0; Guadagnino et aI., 
2007). 
In most of the literature regarding the use a multidisciplinary nurse 
practitioners/nurses played a central role coordinating HCV therapy. Nazareth et 
(2008) and Pozza (2008) the role of the nurse (NP) managmg 
patients undergoing HCV treatment with ancillary collaborative ... <lr't",,,, .. ,,, other 
professional disciplines. Nazareth et al. (2008) introduced ... , .. ' .. ". Model 
of Care in an Australian study. This describes how trained nurse 
practitioners provide increased opportunities for '"u ... "''',<-'''' management, assess 
Iaclcors associated with the HCV, mcrease of in which 
individuals could be screened or treated for hepatitis. (2008) reported specific 
benefits of the nurse practitioner in treating the a study examining clinical 
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evaluation and management in co-infected (HIVIHCV) populations. In study, NPs 
education support in side management. 
patients can be successfully 1'r",,,,1'P'rI a multidisciplinary approach and 
collaborative efforts between physicians, NPs, and other health disciplines 
sum, the literature ~ .. , .... ", to the use of a multidisciplinary 
approach to hepatitis C treatment suggested increased rates of treatment success. 
Collaboration among professionals from a variety health disciplines ensures 
assessment of with an rnrlrn'" ..... chance of "",1"P""1'" completing 
treatment. Limitations of this review include the lack of controlled studies describing a 
multidisciplinary approach to hepatitis C treatment. This includes the inability to 
generalize use a multidisciplinary approach in open access settings as most of the 
literature LV""':>'-'U on vulnerable populations challenged with a specific treatment barrier. 
Integrated Models 
The term ...... 1'''',-. .. '''1'''',; 1S "'''',un,,,,, as "combining or coordinating "","" .. ",'t", 
as to provide a harmonious, interrelated whole" (Dictionary, 2011). This type of care 
model for the HCV attempts to assure collaboration of services for vulnerable 
populations. In 
fragmentation, improved 
mt~egratea models of care for treatment reduced 
increased coordination of 
care. Incorporating the professional services a variety of health disciplines was similar 
for both multidisciplinary model care and integrated care models. Yet, the 
integrated approach the literature review directed care more often to the patient's 
specific barrier to successful treatment. 
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Eleven articles were reviewed involving integrated care strategies in HCV 
treatment. Four reports ""'F>F>"'':; an integrated approach to HCV treatment for individuals 
with current or fonner illicit drug use (Birkhead et 2007; Fahey, 2007; John-Baptiste 
et 2009; 2007). One study the benefits of an integrated approach 
for psychiatric illnesses and treating hepatitis C (Knott, et aI., 2006), and two studies 
described the use of an integrated approach with persons who were co-infected with 
HCV IHIV (Palepu, et aI., 2006; Clayton, & Chang, 2003) . 
.. "',...·"' ... rI et 2006; Hill, Butt, Alvarez, Krajden 2008; Ho et ai., 2008) 
explored the advantages of an integrated care model. Two articles discussed benefits 
of integrated care in gerlenl1l2:au'OI and not within "''''~'vu .• v vulnerable popUlations 
(Garrard et al.; Hill et and the third """""u,,,,, .... care veterans or without 
psychiatric illness or substance abuse (Ho et aI.). 
they exist, integrated care models support collaboration among professionals 
in addiction treatment, evaluation and infectious u,,,,v,,,,,,,, 
Successful HCV treatment is often dependent on comprehensive pre-therapy evaluation 
and treatment of conditions that pose a risk to therapy outcomes. Historically most 
individuals with 'u~, .. ".u illness or substance abuse were deemed ineligible HCV 
treatment. With infonned support from integrated team members, some practices are 
conditions are no an absolute contraindication for treatment 
(Birkhead et aI., 2007). To support these '"''''''''''F>'''' 
Study Liver (AASLD) recommended 
American Association for the 
treatment guidelines so that 
treatment would not automatically withheld from persons with current drug use 
treatment should be considered on a one-to-one basis (Ghany et al., 2009). 
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additional considerations evaluating illicit drug users for HCV treatment 
include the risk of continued transmission should they not be treated, risk ofre-
infection once 1"r",,,1''''/"1 
while on treatment. 
and compliance concerns regarding contraception requirements 
of the eleven reviewed the incorporation an integrated care 
approach HCV treatment as a focus (Hill et 2008; John-Baptiste et 2009; 
et aI., 2006). These studies were done in Vancouver, Columbia; 'or<mtc), Ontario; 
and Minneapolis, Minnesota, respectively. Both Canadian studies used an integrated 
approach to HCV treatment in a community-setting; the study was done in a 
-1..I"""vU Veterans Administration (VA) facility. 
Hill et a1. (2008) examined the benefits of referring patients with 
local community-based program for educational programming and treatment. 
C to a 
this 
study, in just over a four-year period, 1 individuals were sent for UAvun,,'LU evaluation. 
Seventy-four percent of those r",1',o.rr,>£1 r'>l"'plU~'n education but only 26% were deemed 
treatment. Of 363 initiated treatment outcomes vv •• vv.v .... on 205 
individuals. Sustained viral response was achieved 61%. In sum, of the original 1795 
individuals sent evaluation, only 126 completed HCV treatment and achieved 
sustained response. nUIPH.'r this study .... ., .. '''',..,'.£1 success in integrating partnership 
between physicians and nurses leading to an increased number of people served. 
John-Baptiste et a1. (2009) completed a rph''''C'''''''l'''tnlP study looking at HCV 
treatments within Ontario Addiction Treatment "'-'VA,""" (OATC) 
model involving hepatitis nurses, psychologists, an infectious 
an integrated 
specialist, 
primary care providers. Pretreatment screening was performed nurses over a of 
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aef:mt::a eligible treatment were seen for at least one consultation by the 
u ... ,'v"", ..... physician prior to starting therapy. Of the 4000 individuals seen at the 
OATes during the study period of November 2002 and January 2006, it is estimated that 
50% of those had Of the 2000 with HeV, only 109 «6%) 
rp.I',p.",,,rI at least one interferon injection. Study outcomes concluded that HeV treatment 
can co-exist with addiction treatment with the support of additional specialty practice 
partners. 
remaining research study used an integrated approach to HeV treatment 
the core elements of routine screening for psychiatric andlor substance use 
the a psychiatric clinical nurse specialist (peNS) within the 
veteran's facility (Knott et 2006). Psychiatric screening tools were used to initially 
evaluate participants who were eventually divided into four £''''1''''n,~ .... ,,,,, patients without 
positive parlenLs with "' ........... v ... u,"". who saw a peNS (alone or 
additional to a mental health provider outside the clinic); patients who positive 
saw only an outside 
screening but health ".,.T"lJU·'" 
screening, 149 had at least one positive screen. Of those who started treatment, 34 were 
in the peNS group, 8 were treated by UA,",'''~A health outside the clinic, 6 
treatment they opted not to accept mental health """"'''1(',>" The importance 
of this study focuses on integration of psychiatric services within the hepatitis clinic. 
seen, mental health Wfles:ses and ;:'U'-';:'",:;Ul\.,,,", use are to Hev 
treatment and an integrated care model can support early interventions those at risk. 
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The remaining literature regarding the use of .... 1",P£H">1""'./i models of care for 
treatment discussed with 
and 
fragmented 
Garrard et al. (2006) 1""'"",1"\""-,,,,, barriers use integrated care included 
systems; financial disincentives when psychiatric are 
obtained outside of the treatment program; and on individual health barriers 
while other may be over looked. In contrast, Stringari-Murray et al. (2003) 
suggested benefits in an integrated approach for individuals from both HCV and 
HIV. study described HeV incorporated into an already established 
HIV I AIDS specialty in Marin County, California. Recognizing that persons at 
for HCV IHIV are also at risk for acquiring other infectious diseases, true integrative 
services included appropriate ",,,.,,vJ'UAJ.F, examinations. servIces was seen as a 
way to v ..... ,uu.""" healthcare resources. This study inconsistently described participant 
numbers these concerns study validity. However, 
certain barriers such as alcohol and use remained high and a significant number 
patients reported psychiatric illness. Additional barriers requiring further work up 
included of stable insurance, and the comorbidities. 
Developing partnerships with mental health services, establishing a case-management 
program, most importantly, cultivating the of the nurse ..... .,"ht'l"\n with 
guidelines were suggestions posed by the authors. 
In sum, the literature reviewed on integrated models care support approach 
to treatment availability with hepatitis However, are 
discrepancies in literature that support fragmentation of care with type of model. 
This model focuses on integrating services HCV "'V~''''VUUAr.. 
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treatment locations 
individuals are already receiving services for substance use or in community-care 
settings. consistent benefit nurse practitioners or clinical nurse specialists in the 
management of treatment was highlighted. 
Shared Models 
articles were reviewed involving a shared care model approach to 
treatment (Belfiori et al., 2009; Ewart, 
& UI ...... :>l\J.. 2006; kOiltorm 
Joyner & Safe, 2004; 
Tait et aI., 10). 
Gordon, 
of the 
studies were research studies that utilized shared care model in treating hepatitis C 
et aI., 2009; Kontorini et al., 2003; Tait et 2010). 
conducted outside the 
respectively. 
specifically Italy, Australia, the 
studies were 
Kingdom 
The care models in studies examine the benefits of involving 
mUltiple disciplines manag;ement of 
insights to the advantages of "sharing" 
treatment. 
work load when considering 
provide 
intensive 
treatment "E'>'''U"U>J for patients and time-intensive monitoring 
providers. By sharing responsibilities, increasing the availability appropriate screening 
protocols and improving 
noted. 
mcaLllageInelt1t of side effects, increased compliance rates were 
Belfiori et (2009) studied 52 in Italy in a drug maintenance program. 
This mUHl-cernre pf()Spectlve 
2006. Of the 52 individuals 
observational study was completed between 2003 and 
met inclusion criteria, 45 completed treatment of 
achieved a sustained response. program included addiction specialists, 
specialists infectious disease, and psychiatrists. Frequent monitoring by members 
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the team allowed for early interventions and treatment modifications. This study 
suggested hepatitis C treatment success when treating IVDUs who were on 
methadonelbuprenorphine was possible. 
The shared care model reported in prospective study (Kontorinis et 
2003) varied slightly that surveillance monitoring was shared with the general 
practitioner. This approach included hepatologists, nurses, 1"11'11.,,<=11"'<' care providers, 
.:IV"."","' .. .:IL,", from disciplines offered psychiatric support. Hepatitis C treatment 
was initiated by the hepatology staff and followed with routine monitoring of blood work 
and visits the 81 patients trp<=ITP'i'! 54 had 
failed attempts of HCV treatment. In this study. 40% of patients achieved 
sustained viral reSpOlrlSe and of those, 24% were genotype 1 58% were genotype 
By using a shared care model for H CV treatment between np""pr<=l f't1T',I'\""p1'Q and nurse 
practitioners, 
increased 
authors reported treatment regimen compliance rates of 98% and 
confidence. 
last research study reviewed the shared care <u .... 'rl"\<'t>h (Tait et 0) to 
HCV treatment looked at Managed Networks (MCN) as a means to enhance access 
to C treatment. MCN added new pathways referrals which included 
non-medical referral from addiction services, prisons, and outreach nurse-led 
Using this model, the access to HCV a /L_"",., .. period, in this study, rose from 
61 to 82.4%. et these are 
in-network collaboration significantly increases access 
with previous reports that 
individuals traditionally 
difficult to locations. 
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Two articles on a shared care model approach to HCY services addressed "'1-'''''''''''".''"' 
practice nurse in the 
2004; Hamilton et aI., 2006). 
benefits with an increased role 
management of hepatitis C 
showcase the value of nurse 
surveillance of appropriate 'UUVLI .. t>V> 
patient education, side effect mana:gernellt 
within their scope 
psychiatric and addiction ':>IJ"''''''U':> 
able to appropriately 
" .... ''" ... '"''', and oo:se-a01ustmelrlts. 
liver specialists, 
primary care providers, nurse 
treatment. 
In sum, the literature reviewed on the shared care model as an approach to 
were 
hepatitis C treatment focused on access to treatment when limited "1-''-,'''''',,1> 
are available. Essentially, the model uses a multidisciplinary approach, often with 
partners in other disciplines. In a lead nurse practitioner in collaboration 
MCNs offered added benefits to "''''"''-'''':>H11:', care 
extended wait times. 
traditional barriers 
Three models of care multidisciplinary, integrated, 
shared care. All three addressed common barriers to treatment and proposed to improve 
access to HCY treatment. Psychiatric and substance use challenged the healthcare 
system to improve care delivery ""'l""""'~" In studies, these at-risk populations 
the highest prevalence continue to the largest group ael:enntrlea as 
ineligible for treatment. National 1:',"","'''''''''''''' now and encourage a ""H''''HI';'''' 
supporting efforts treatment evaluation. By instituting ..... '-',0 .. <1 
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which promote collaboration .... "'1''''''',." specialties and primary care, patients with 
have a significantly greater chance at completing treatment. 
Scholarly Project 
In order to the care individuals C in a community along 
the shoreline of western Michigan, a project was initiated by incorporating 
gained review design and 
hepatitis C focused on cre:aSllng access and ad(lIe~;SmlQ perceived ,",'3?'1"''''''C' to 
treatment. Evaluating community support and perceived need for improved access to 
first step this project. Knowledge from current 
literature the elOom.em and implementation community-based, 
multidisciplinary treatment program. 
In this healthcare disparities for vulnerable populations with hepatitis C 
identified many biopsychosocial challenges. The magnitude ofHCV as a healthcare 
UH'''"'''!.'''''' was highlighted and peak prevalence was forecasted this decade. 
programming, using a multidisciplinary was for 
individuals with HCV. project used the principles of implementation science to 
translate research clinical practice by developing and implementing an 
based to improved health perceptions for people with hepatitis doing so, 
barriers to treatment were addressed and comprehensive HCV care was 
implemented in a cohesive, community model. 
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CHAPTER 3 
CONCEPTUAL FRAMEWORK 
The conceptual framework the Chronic Care Model (CCM) was used to further 
understand the complexities of Cand programmmg 
Ut:l;t:::s:sary to adequately care for individuals with hepatitis C. CCM is an evidence-
based initiative aimed at ,",UL.,",U,'F. the gap between scientific underpinnings and quality 
patient care (Oprea, Braunack-Mayer, Stocks, 2009). The has been 
by individuals who seek to improve chronic illness management with cohesive and 
collaborative partnerships between patients and providers. Although the CCM was 
developed use care, it applied to a of health care 
and targeted populations (CCM, 2010). CCM focuses interventions on mam 
components care: community resources and healthcare organizations; self-
management support; delivery """"Pfrl U'v.H,""U. decision support; and clinical 
systems. Each offers vital smlte~~leS to augment the care lag,em,ent of the 
chronically ill (CCM diagram, Appendix A). 
The CCM can be implemented as a whole, or as individual components. Both 
approaches aim to improve care by coordinating treatment activities. The complete CCM 
has not undergone "'-V.'UUJ controlled ."'''' .... 1''. 
in well-designed studies. 
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components have been 
UL..<U,,'U of components of the CCM 
been studies exploring congestive failure, asthma, and diabetes. a 
of 39 studies by JJUU\VA.1.W .. ,HU."'l and Grurnbach (2002) examining 
care the authors reported 32 studies showing improved outcomes using at 
least one process or outcome measure. In this review, no single component CCM 
was found to more than the Additionally, number of CCM 
components was not a determining factor improved outcomes. 
need to address chronic care management is highlighted by .l.JV ..... vLJ,.U ... UU"', and 
(2002) as "tyranny of the urgent." 
anxieties experienced by patients who are more concerned about their acute physical 
complaints than 
Additional 
are in 
care 
on-going management of their chronic illness. 
include mCenlnV(~S for 
the 
include rushed appointment schedules; minimal to little time to review vital laboratory 
values; inadequate education for patients on the importance of medications, diet, 
and follow up care. This phenomenon can especially true for individuals 
who are newly diagnosed hepatitis C who may require more intensive education related 
to their disease. One example is heightened .... U/U".,L"'" experienced by individuals as 
they attempt to identify the source of their exposure to the likely occurred 
decades 
Chronic care 
venues. Individuals 
lagemem takes three 
care from resources in community, healthcare 
institutions, and by a "",r,un,cv of health care providers (Bodenheimer, Wagner et al., 
2002). As the nation's 65-year-and-older population resources to 
illness will be at its Baby boomers vU"""_HF,'" traditional approaches to care 
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and continue to show more interest 
Holman, & 
and self-management SITl:llrell 
~UAV"''''U. 2002). By applying 
in their 
care (Bodenheimer, 
CCM, patients are navigating the complexity of overlapping healthcare 
through development of collaborative practices. 
Chronic Care Model Components 
Community Resources and Policy 
Advocating for changes in healthcare policies is an important step redesigning 
how chronic care is delivered in the community. involves rethinking on the 
and changing part of community, institutions, leaders. 
outdated healthcare delivery policies and avoiding duplication services are examples 
of health care that 
2010). These changes 
help 
efficiently 
the of chronic care management (CCM, 
costs enc~oUlfa~~e newer, innovative 
approaches to care. This may to improved coordination of care across organizations 
patients to 1"I<I."1",(',n<1 chronic care 
programming. 
Healthcare Care Systems 
One ofthe primary goals ofthe CCM is to create cultures, and 
mechanisms that promote safe, high-quality care (CCM, 2010). To accomplish this, 
senior leadership within are now to in redesigning chronic 
care lanag<;:m,ent facilitating care coordination within between 
coordinating communication, and sharing data across healthcare settings. Continual 
nT,v"",,"'" improvement was ,",,,,,un, ... an essential for healthcare systems as ,",,,<UClA"' __ ' are 
m to errors or newly defined healthcare problems arise. 
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Self-management Support 
Self-management support is one of the most important elements CCM. 
Regardless of the setting in which patients receive care or by whom, patients are 
held accountable of their chronic illness. Establishing collaborative 
partnerships with healthcare providers and patients changes the paradigm of "who is 
control." Self-management is highlighted a contemporary compared to 
traditional types of care where are control (Bodenheimer et aI., 2002). By 
working collaboratively and encouraging self-directed behaviors, patients can make more 
informed decisions about their care that will serve as further motivation for continual 
Collaborative care is a driver encouraging patients to take ,",Ul"'''''"'' of 
their illnesses (CCM, 2010). In traditional care delivery systems, physicians are the 
instructions on treatments, evaluate outcomes on 
compliance (Bodenheimer, Lorig et al., 2002). collaborative care there is 
mutual respect providers as being the most knowledgeable about diseases but patients 
are recognized as the expert on themselves and their lives. Jointly establishing 
achievable goals in treatment and evaluating outcomes based on patient's expectations, 
confidence, and motivation can ultimately invigorate sustained change. It is important to 
note the CCM that the emphasis shifts towards the patient being 
with education by healthcare 
Lorig et al.). 
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primary care 
(Bodenheimer, 
Delivery System Design and Decision Support 
Components CCM support the integration of evidence-based care in 
part of the """'T"",.,.. ..... 'v,"',!".", defining team member's roles 
and responsibilities improve efficiencies and effectiveness of care delivery (CCM, 20 1 0). 
Additionally, utilizing case Hl".ua~",",u complex and evidence-
care supports gm~r-~aarLoaros in care delivery and encourages appropriate follow 
up care. Collaboration between specialists and primary care providers offers continuity 
and ........ vuF. healthcare systems (CCM). 
Clinical Information Systems 
The 
world of 
component of CCM is clinical information <'''''TA''''' In the advancing 
pertinent data can be 
eXl:ratJolatea to ensure comprehensiveness treatment plans. Patient registries are a 
central component to CCM (McEvoy & LaA,au,"" 2008). act as a 
means to necessary surveillance testing and follow up schedules. By doing so, 
these registries a proactive approach to chronic care management (Ortiz, 
2006). Registries can be established without availability of an electronic health 
most facilities access to common software tools such as where 
"F'."'>""''''':> can be formulated (Ortiz). Electronic of care 
and communication patterns between providers care (CCM, 201 0). Ancillary 
and correspondence between providers are examples where coordinated efforts are 
encouraged within component of the CCM. 
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CCM and a Community-Based Hepatitis C CUnic 
The Chronic Model provides a conceptual framework to further the 
complexities of treating individuals with 
address explicit challenges in providing 
of the model components 
to this population. The model serves to 
U"'.llUJl>L." the between research and practice by C'll .. , .... r..ri the use evidence-based 
practice and a collaborative approach to care delivery. The CCM was used as a 
framework for program development the community-based hepatitis C treatment 
clinic along the shoreline of western Michigan which was conceived as a DNP project. 
Although model as a whole was used to guide this project, focus was placed on the 
self-management support and decision support components developing the HCV 
treatment nrl"rrr'<:>rr.""', 
improve chronic care management for individuals with hepatitis C this 
community, 
resources. 
of project included increasing awareness of community 
example, one community to solve 
to inadequate healthcare p,.n.,,,,,r'.> and lack of social services. by 
this agency \JH'-,VUL patIents to participate in educational programs on u..I':'.""a.:>"" 
management. Collaborative efforts established with this type of community agency can 
the the HCV treatment 
As a healthcare C'uC'r"",..,."" component the CCM, ""0'.",..., and cultural 
were a major focus of this project. highest rates of hepatitis C continue 
to found UUJ."""""'''' populations. It is the term success any 
HCV treatment program providers and staff convey supportive, non-judgmental 
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attitudes on "how, when, where" people were infected. This 
of hepatitis C 
improve health outcomes. 
at the same conveys partnerships to 
Self-management "UIJ'lJV' was the primary component used project. 
treatment regimens Care nt"'"''''''''' and require the patient to adhere to 
monitoring In addition, most patients medication side <>TT<>I'TC' which 
require self-management at home. may include treating skin adjusting 
nutritional intake to nausea, and/or 'V'"""''''''''''" activity to reduce 
Establishing strong patient-provider relationships encourage a collaborative approach to 
self-management as it ."'" •• "'''' to hepatitis C treatment. This includes vital education on 
the anticipated treatment regimens; 
and required follow up care. 
Decision was another "" .. ","nt. 
expectations 
component of the when """"","'-'1.'';)1<)'1<5 
this community-based hepatitis C treatment clinic. most ......... A'r1""""t "" ... """t" of 
was to develop an evidence-based, innovative approach to improve health 
outcomes. guidelines current literature the approach to care 
delivery established for this community-based clinic. Collaborative partnerships 
were developed ~.,,~ ...... 
healthcare ..... "vll-flU) • ...,". 
local prc)te!,SHma:1S to gather ....... "I1P'11 variety of 
To provide for '-"'-''''H1,'''- education of patients and 'UJAn"'"'' 
relative to hepatitis C, written materials were for accuracy. importantly, 
to be involved in decision-making whenever possible during 
their hepatitis C treatment. 
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Lastly, congruence «u"vu.!". the clinical information in the community-
hepatitis C treatment clinic was challenging. Although the hospital 
had complete access to electronic health (EHR), the HCV clinic did not. 
Therefore, all documentation and communication was 11.11 ..... " .... with copies or 
verbally by telephone. The quantity and coordination paper documents proved to be 
and cumbersome. was redundancy paper charting in to 
adequately for a monitoring ""<,t,,,.n As a new clinic in an already 
established ambulatory setting, multiple challenges were encountered including a lack of 
community awareness of hepatitis C services; shared physical including phone 
machines, poorly coordinated document exc:nrulge and miscommunication; and 
and an unorganized process for scheduling patients. 
Summary 
The chronic care model can be used to the care u.,,'u ... !". .... for "''''.VUj,,,, 
illnesses. This model CmIra,~eS collaborative efforts healthcare professionals in 
to evidence-based care. Using the components the CCM provided 
clarity guidance program development for this community-based hepatitis C 
treatment clinic the shoreline of west em HH'VUj'F;"'''' The components of self-
management support decision support especially guided treatment programming to 
address known to hepatitis C treatment Ultimately, the quality of provider-
lJ ... w,,-,.n relationship had a impact on the ability to manage chronic 
illness. Using the CCM, the project remained focused on mcreaSml!! access and 
health t'\p"(,PlntU\t"i for individuals with hepatitis C. 
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CHAPTER 4 
METHODS 
purpose of this vU'''UL',",' is to describe methods and used to 
develop and implement a community-based, multidisciplinary hepatitis C clinic in an 
west Michigan. underserved area near the L""",,",,_"CL"'L 
COllceptulau:zea in four .!],'~~_!],·~:r''';H'''''''' phases (a) 
project 
of community (b) 
development and implementation of a community-based n""''''T1!T1 C clinic, (c) 
program including summary assessment of barriers to treatment, and (d) 
1"'Ir~\rrr"'rn outcomes as relate to rnr,rn"J .. n access to hepatitis C care. This 
occurred hPT1,X!p~'n February 2010 and 2012. 
need to improve care for individuals with hepatitis C west Michigan 
community of mtc::re:st was a long-standing goal for heaIthcare providers. 
primary care providers sought solutions to the lack adequate care patients with 
hepatitis C by first approaching senior administrators from hospital .""",t"rn 
to find solutions occurred in spring of2010 the sudden death a local 
physician who was treating numbers of served as one the few 
sources care for n"'rcnn with hepatitis 
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Establishing Hepatitis C Initiative 
The Community HCV Initiative was a grass roots effort by interested 
professionals and the concept was presented to hospital administrative leaders in July 
2010. With resounding support, a taskforce steering committee was comprised of a 
doctor of nursing practice (DNP) student; a local physician specializing in infectious 
diseases; the executive director of a community agency focused on services for the 
underserved; and the Vice PresidentiChiefMedical Officer of the hospital. To 
adequately access the problem and determine the best evidence-based approach to 
program development, ample time was taken to review the current state of knowledge 
related to hepatitis C. The DNP student assumed responsibility to review literature on 
HCV treatment models and summarize existing guidelines on treatment management. 
The review of literature on hepatitis C was limited relative to optimal models of 
care delivery for persons with hepatitis C. The review reflected a growing interest in 
HCV care and reflected the limited number of published studies on HCV models of care 
in the US. The review also included several studies from Australia and Canada 
describing particular challenges that were encountered as HCV -dedicated clinics were 
established in their local communities. Consistently, these findings suggested that a 
collaborative approach using expertise from multiple disciplines would be useful in HCV 
populations. 
Congruent with the established timeline, members of the Community HCV 
Initiative steering committee met in January 2011 and reviewed the initial literature on 
models of care for individuals undergoing HCV therapy. A mUltidisciplinary approach 
was selected because ofthe dominance and success with this type of programming in the 
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literature. A multidisciplinary approach to HCV treatment was £1PI'PTlCr1 as the 
clinical approach to address 
U";;va,J,;:>v of the success with other 
by those ala:gnosea with HCV (Appendix C). 
models in countries, administrative .~~.~~"v 
of the hospital requested a draft job description a nurse practitioner (NP). The request 
included a ~'V,'U"''''U'U ne4:::esSary education, 'V-",,""'LL'" and a list of skills 
ne(~aea to manage HCV treatment in collaboration with an infectious disease physician. 
During this meeting, a list of potential community stakeholders was developed with the 
the HCV '.U"\.'HUl.la and explore 
opportunities for partnerships. For the purpose of the nr"'\lp'~T community stakeholders 
to to 
were defined as "n~'r<!r,n who have direct or indirect influence on the quality of care for 
individuals with hepatitis " 
Meanwhile, to better understand the needs of local primary care providers, a 
Community HCV Assessment was developed. This survey was designed 
to examllle HCV _~ .. " .. ,.., behaviors of 
and to explore barriers, including access issues to HCV treatment. The was sent 
with an introductory cover letter (Appendix D) explaining project to nearly 200 
physicians, nurse practitioners, physician Unfortunately, email 
included pediatric OTIICeS who were unlikely to 
treatment. Community C Needs was 
deployed electronically through Survey Monkey on March 18th 2011. Of the nearly 200 
providers surveyed, (11 responses were collected. Although the survey response 
numbers were limited, the additional comments submitted by PCPs were helpful in 
delineating need comprehensive community pn>gr;ammlng. 
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next III was to meet with nn.1t", ... t. 
who be willing to act as "partners 
took place on April 2011 and included members 
community stakeholders 
A taskforce meeting 
HCV Steering Committee; 
the local community public health department; pharmaceutical interested 
community "r.'~U,""V'" healthcare .... ~".,,~Jlu.'"'..., to address psychosocial hr.>? .... "" .. " to 
treatment. Physicians and leaders local Federally Qualified Health 
(FQHC) also attended in an ",rr'>t'YI1n.i" to network with key players involved in the 
Initiative. 
During this taskforce meeting, a short presentation on the dilemma of HCV, 
barriers to treatment, and a review of literature on various treatment models was 
Additionally, the of the Community Needs were reviewed 
and discussions ensued regarding the implementation of a community-based clinic using 
a multidisciplinary model. 
a result the taskforce meeting, committees were to ",£1ri .. "",,,, 
various sUbspecialty 
of the 
oet:mt::o essential for a dedicated HCV treatment clinic. 
committees met with the DNP student and, when indicated, the 
collaborating un,","'''J'''''> disease Dn'VSl~'::IaJn. The VV',UH .. met at various times between 
April 2011 April 2012. 
Multidisciplinary Partnerships 
order to establish multidisciplinary partnerships among six subcommittees, 
the DNP student met with various members on 12 occasions to discuss collaborative 
"'++"....+" in improving care individuals with hepatitis C those _ •. ~.~.,.,~ treatment. 
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Appendix G is a 
HCV clinic. 
listing of all potential mUltidisciplinary partnerships for 
Psychological and addiction services. January 12, the DNP student 
presented to a group 
challenges of ""''''4'''''",-
the presentation was to 
50 community mental 
C in individuals 
the eligibility 
case workers to describe the 
One main 
hepatitis C treatment 
the need for evaluation on a case-by-case basis. Some case workers among this group of 
professionals voiced concerns as they acknowledged rates of ineligibility among 
their patients with ''',",uu"", illness. The case workers were educated on the need for an 
extensive follow Up .".au,."" common medication 
eligible for treatment. 
evaluation, _"'J>~""'_~' referral, and 
multidisciplinary were shared and 
""'/"'/",><,1",, for those deemed 
initial HCV clinic 
clear and consistent 
Community "' .... " ... " .• ""'" Members from community agencies met to 
discuss resources 
information 
U",""H'" for the underinsured and individuals. This included 
prescription services. 
Options and resources 
providers were also 
case management and in locating primary care 
To address the for reportable diseases, a nurse from the community 
public health met with the DNP student to 
importance of communicable diseases 
educational route of HCV ,.<>"",(\1"1", 
established databases. the public health rt" ... ",1"1"'n'> 
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policies regarding the 
of appropriate 
laboratories to 
attempt to cross-
reiiereJtlce:d all V"".lvU'''' from historical databases pennanent into the Michigan 
Disease (MDSS). 
Pharmaceutical On multiple 
met with the DNP student and physician to 
phannaceutical ref)re:serlta1:iv(~s 
issues related to HCV education and 
treatment. Phannaceutical representatives provided infonnation on patient assistance 
nrr,crr<.rn" as well as provider and oalCleIU educational infonnation. medications for 
HCV treatment are extraordinarily expensive and often pnor ......... ,,'v .. (PA). 
It was concluded that filling of prescriptions might occur in a variety of ways. 
benefits specialty include refills; In 
the P A oro,~ess providing additional patient educational materials; and some cases 
assistance laboratory monitoring. HCV clinic is housed in 
ambulatory care the use from "LI'-' .... 1<,"' .. 
conflict the local hospital phannacy. team and 
communication a priority. Additionally, a hospital phannacist was approved for 
part-time employment in hepatitis C although of this appointment 
had not been confinned at the time project conclusion. 
Michigan Hepatitis C Advisory Taskforce. The DNP student met with the 
Adult Viral Hepatitis Coordinator from Michigan Department of Health 
(MDCH) to discuss policy issues in state of related hepatitis C. The 
coordinator " .. <un.,,", the Michigan Hepatitis C Advisory Taskforce 2007 to 10. 
This governor-appointed Force ,",V.<U .. ,,,,", 21 recommendations J.V\',U':>.UIF; on the 
following priorities: Increasing hepatitis C surveillance efforts/improving the quality of 
hepatitis C surveillance data; developing needle v"''"'U''''''F,'' 
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,",U'-'UAF, syringe access; and providing other hepatitis to people who 
use drugs; and facilitating access to hepatitis C screening, testing, management 
treatment (MDCH, 2010). 
Educational offerings. further develop their providers at 
the clinic attended several seminar and educational opportunities. These 
increased knowledge confidence of the providers in treating hepatitis C patients 
with Direct Acting Antiviral (DAA) in combination with interferon ribavirin. 
Planned educational events by physicians from tertiary, research institutions offered 
expert on HCV treatment regimens and challenges. In addition, an infectious 
u,.,,,u~ • ..., colleague another community met with student the 
collaborating physician to review treatment guidelines, discuss community reterr,al 
options reimbursement, and ~ol:")~~' strategies for monitoring. This opportunity 
the to insights C treatment the standpoint of a 
community-based clinic. 
DNP student spent immersion in another community-based HCV 
treatment clinic managed by a nurse practitioner infectious YAY',",U.,,, physician. The 
experience allowed the student to gain ... ~.,.., ... ~ into IJ"'Ll,""UL processing, treatment 
protocols, monitoring strategies, and develop networking relationships with 
collaborative team treating hepatitis C. 
Collaborative Efforts with Federally Qualified Healthcare Clinics 
To ,Tn ...... ,,""''' the care individuals with hepatitis C in the members 
local the DNP student, infectious disease physician met to discuss 
collaborative efforts to optimize access, oU1:COlme:s, and reimbursement servIces. 
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majority of individuals with C psychosocial 
challenges as well as health and financial concerns, it was ",,,:.u..u,,,,,,, a portion of 
patients with hepatitis C may be established patients 
collaboration between the FQHC healthcare ............ ,H." 
was seen as important a way to measure 
Hepatitis C Treatment ...... ,~ ..... "' ..... 
The of program 
DNP completed over 400 hours of clinical 
community partnerships, plan and coordinate clinic prc)gnmllmn 
approval for program evaluation. 
Program Evaluation 
Setting and Participants 
care. 
to 
obtain 
1. The 
The hepatitis C treatment clinic was established in a ,.,A ..... """"" "~.'OJ~~~' located 
along the shoreline of western Michigan. 
to evaluate the effectiveness of HCY treatment a mUlltl(llS(~lPJ 
setting. Clinic programming sought to overcome perceptions 
population included all adults with HCY uu~~ •• ~ .. over 18 
agreed to participate, and ~L""'''~~ " ........... ,...,,.... .... 
to allow select data extraction from 
consent documents were maintained as part of the ..... "t • .,.",!' 
was seen as essential 
to care. The 
who met 
inclusion included those individuals referred to the hepatitis C clinic for 
evaluation of treatment. Exclusion criteria included those who did not 
consent patients under the age of 18. 
55 
Instruments 
JLJL ... ' ......... perception survey. A 
"vllUU'-,U to data regarding oel'celDtU)llS 
hepatitis C treatment. Select 
and variability relative to no".",.,T 
treatment programming. Demographics included 
(Appendix I) was 
resources believed to llUIJU\,. 
data was collected to detennine 
.~ .. ,u ... _u to assist in further 
gender, hepatitis C genotype, 
C treatment history, and the county in which the patient resided. was 
PVT'1'l'l,...TPI1 on and frequency 
programming 
collection steps. The survey was 
however, timeframes between 
personal 'I"'I1',·t"""",, in starting treatment and any 
np,'U'F,.,n the various surveys. 
first survey collection 
U,uI\,.UJUL (Appendix J) 
The 
minutes. ~ .... ,... u completed the surveys by 
reterr'als to provide 
mtt::rested stakeholders. 
to patients at five specific 
varied among patients due to their 
testing/consultations 
the patient received the Patient 
to complete short 6-question 
completed in less than 5 
along a 200rnm line 
indicating their perception of the illness questions. A potential 
discomfort a patient may have included an A ..... ..., .. ,'] to comprehend what the question 
was or an inability to read. In these cases, nurse was available to 
the 1.1""',""" with the survey. Completed were added to the ....... ."v ... 
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se(:onld survey was to physician consultation 
of the survey I"'\I'"f'ol'P'"'' Again, the 
.u ...... ..., ... " .... with an "x" to reflect their perception of the illness-management 
third survey was distributed at 
management session and 
The fourth and 
seCIDnd follow up (2 and 4 weeks 
a manner congruent with other surveys. 
time of the injection 
in manner above. 
were distributed at the 
treatment) and completed in 
Informed consent collection. Informed consents were collected by the nurse(s) 
who 
to 
in C treatment clinic . were trained by the DNP student 
questions. to 
of data 
.,." ....... ,,<."" of the project and to answer 
nTr\'I""YY.ArI consent was requested V""''''UL.;) who were receiving 
treatment at 
who were no 
discuss the 1"'\1'"(\1PI'T 
revIew 
a scripted approach 
obtaining services at the clinic, nurses 
request consent. Patients were 
consent if they agreed to allow access 
Institutional board. A request 
submitted by the Institutional Review 
State Mercy Health Partners, Muskegon, 
This project involved selected information from 
obtain program evaluation data for the community 
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For those individuals 
to contact to 
to come in person to 
medical record. 
<>T""tTr.""'T 1-4) review was 
at Valley 
-"'l"~" (Appendix Land M). 
patient surveys to 
C treatment clinic. 
Data collection and evaluation tool. Data collection was accomplished by using 
a retrospective chart audit of existing medical records to examine selected demographic 
information and data regarding of available resources believed to 
treatment. was obtained from patients seen at the between October 
1,2011 and March 15,2012. A Hepatitis C Treatment vrnn,.<l1'Y\ Evaluation Tool 
(Appendix N) was created and health oer'cel:'ltlC)ll 
To de-identifY patient information, a corresponding sequential alphabet 
character was ~u,."" •• _~ to each participant. The DNP student only accessed medical 
charts of who agreed written consent and only a.I.J",I.J";~I.JU medical 
,",'-'V'l"'.;) once unless <UH,HUJLVH of the was required. The character code was 
marked only on program evaluation A master of participants was 
password orc>tec:ted computer a secure site. 
The results health perception questions were reCO[(lea by measuring 
point where patient has marked an "x" along a 200mm line. Quantitative 
.... 'V ..... u,uu." .... by measuring 
their responses. 
Program Documentation 
length from zero; a2mm equated to 1 % 
ona 
were 
At the time of programming development, electronic medical records were 
not accessible clinic areas within the hospitaL required creation paper 
assessments and monitoring UllJLI.JHLULJlVU forms. forms COITe~;oondt~d to the 
organization of the ...... ', .... " ... chart" as dm~cte:d by the physician. documentation 
developed community C clinic can be in Appendix 0 and 
U''-''LU",,,, a Problem with effect mama:gernellt strategies; Notes; 
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Medication Reconciliation; Pretreatment 
Flowsheet which 
dosages; Intake 
documented vital signs for 
History; and Laboratory 
Laboratory Monitoring 
and treatment medication 
In addition to forms for the medical record, .au ..... ""' .... ",,'"'u letters were 
developed to 
(Appendix 0). 
communication between 
... '"' .... ,."''' correspondence to ophthalmologist/optometrists 
individuals requiring pretreatment eye exams and a to primary care providers 
informing them that their patient was seen at the but required additional or 
referral. A specific was developed to the primary care providers addressing mental 
illness concerns active alcohol use. 
an additional informed consent C treatment was 
completed. mt4)mled consent addressed Llve,,",u ... treatment side effects; 
medication and follow up compliance; and contraception information. Patients were 
asked to sign the consent before starting treatment 
Clinic Service Coordination 
Treatment 
One of the most important steps in 
to have a "' .......... 'lB5 of national 
published guidelines as an addendum to 
hepatitis C treatment 
treatment. The most recent 
published previously (Ghany et 
was 
2009,2012). 
for treatment 
avoided. 
LUY.,."U' .. "'" encourage patients to 
this way former myths 
i:1:::':::"C;:::'~'C;U on a one-to-one basis 
eligibility requirements were 
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Clinic Protocols 
Clinical protocols refer to the algorithm of how lJ'U'''l1C;) were rp1",~rr"11 and 
how access the C clinic. with any new program, there 
was flexibility in these protocols until more knowledge was gained through experience. 
Referrals. Patients were referred to the clinic in a variety of ways. The ..... ~.T""·.., 
method was a or phoned 1'''t"'~rr''' from 
allowed patient information to accompany 
added of 
October 1, 2011 and 
that the clinic was available for referrals. 
,... .. 11m""",, care provider. Faxed referrals 
requests; phoned referrals required the 
received between 
word-of-mouth .... u."' .... 'u..",,, 
HCVeducation. Adequate and accurate education was seen as imperative for 
patients hepatitis C who were COilSHlefJtng treatment (Birkel, Caldwell, Stafford-Fox, 
Casarico, & Benson, 2004). design and development of the hepatitis C treatment 
program '"'''''_'''C ........ models literature and design clinic played a key role in 
determining how would be educated and processed the clinic et 
aI., 2011). As established, the program enhanced education of the patient on 
reviewed term ofHCV; described treatment and possible side effects; 
and patients on the em~ClS of alcohol and HCV. During the clinic 
evaluations were made 
compliance concerns were aa(1reSSt~a In 
scheduled in a group setting. Most importantly, 
""""""P'C'''' of developing elatlOlnSllllDS between 
team. 
60 
treatment eligibility and medical 
maybe 
initial clinic appointment started 
patients, and hepatitis care 
Physician consults. Patients were scheduled for a physician consultation 
they aTIe:nm~Q the At of the education was reinforced; a 
and physical were completed; additional up studies were identified; and 
""...,.,uv,.", to be answered. Requirements to patients were given time for their 
determine eligibility for treatment involved consideration multiple 1aC:I01'S 
including compliance "".".'-'''', results liver biopsy, imaging studies, blood work, eye 
exam, to psychologist or psychiatrist, or other medical specialty such as 
cardiology, endocrinology, and gastroenterology. 
Pretreatment testing. I-<PTnrp therapy could begin, all pretreatment testing was 
completed to rlplrPM"I"I 
treatment. 
underlying liver ..... J" .. ," •• 'V or co-morbidities that 
information, along with an accurate psychosocial evaluation 
ultimately determined treatment eligibility. Required pretreatment 
Appendix O. 
Announcement Letter to Community Providers 
is shown in 
A formal announcement introducing hepatitis clinic to the community was 
on February 2012 (Appendix In this introductory it was clearly 
communicated that the clinic was first attempting to "' .... '" .. ,,:1 patient volume within 
the community and encouraged primary care providers to assist in referral process by 
having their IJ""'"U.''' complete the required preliminary work 
Hepatitis C Clinic Staffing 
Estimating staffing 
hepatitis servlCes. One 
for the was difficult. Throughout the 
.... T"'rt .. ' .. T (September 20 II-April 2012) coordinated all 
registered nurse was minimally involved collecting 
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collecting infonned clinic rpt,>rr<l 
consents. On a 
nn'"<lH''-'' monitoring. 
.... ""'1V""', a medical was """''''''0'''''''' to the HCV and roomed 
patients signs and weights, prepared charts, and assisted in making 
copies of chart documents. 
a meeting was held with UU"V"'UU"P; physician, the 
uu"'.""'''''''' for the manager, and L",",,"'LV .. ' officer to u, .. ,,., ... ,,,,, "",",U,.HO 
After ...... ,.vv. of incoming rpt,>rr<l 
.p;u,..,.. .. ,'" required for 
monitoring and mama:gernellt of hepatitis C treatment, group agreed to move forward 
with developing a position for a nurse practitioner to work in collaboration with the 
infectious \,11"''''a;:' .... nn'''o'i'' At the time of project 
being fonnulated that would require eventual approval by 
a business plan was 
hospital finance committee. 
operations, a fp.,,,tv,r<,,,-., n,"'Cn'IIU'I was posted the To secure ,,,,,,u,,,,,,,,, • .., 
hospital for a part-time nurse practitioner at the conclusion 
Outcomes Evaluation 
project. 
To evaluate improved access for hepatitis C treatnlenl, healthcare providers in the 
community were <',n''''''''<>£1 at the completion of the project. ",. ... ,"".,'" were completed by 
providers who a Grand Rounds event on survey (Appendix 
Q) mirrored for the Community rl."''' .... '''''1U .... UL in that 
infonnation was HCV screening nr<ll"1"ll'p barriers to 
HCV care, Infonnation reviewed at this seminar included magnitude of the HCV 
dilemma, known 
hepatitis C clinic. 
to treatment, and expected benefits of 
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community-based 
care 
f"Irr"Pt'T was developed with 
individuals with hepatitis C 
assessment was to 
COlffiJ:lonlents in order to improve 
of western Michigan. 
the necessary data required to 
convene and convince institutional leaders to champion this cause. The project was 
and implemented with knowledge F. .... ,,, ........ from the literature review and 
F., .. " ............ ,,'"' from components of the Chronic Early program evaluation was 
assessing the health f"Ip· .. ,..P· .... t'I\t'I 
treatment. an outcome assessment was 
...... , ... .,./""',,'1"'" on their perceptions of the 
place over a two- year 
The community-based, 
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1-" ... ,."' ...... relative to common v ...... '"' .• oJ to 
.. ", ... ,<vu. and analyzed from care 
meeting their patients' needs . 
dozens of community 
hepatitis C treatment clinic is now 
The purpose of this project was to 
report patient's perceptions of common 
treatment. The project was 
5 
access to 
(b) development and implementation a COllliTmnny-oasea 
program evaluation as it relates to patient's ""1",""", ... ,1"1 
e nealmem and 
e 
e clinic, (c) 
to treatment, 
and (d) evaluation of program outcomes as 
care. The results reported reflect the 
""""''''''1"1 access to hepatitis e 
hepatitis initiative outcome survey, and the health perception survey. Data 
the surveys was accomplished by the Statistical 
(SPSS) software. 
Community Needs Assessment 
Approximately 200 emailsweresenttothe ....... au ........ 
network with an introductory note and link to an 
purpose of this evaluation health care providers 
and physician assistants. Results of the survey are shown 
who responded to question one, the 
with HeV in their practice in the calendar 1% 
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a 
the 
had seen 0 
patients; and 17.4% had assessed 11 hepatitis C patients. Questions 
routine screening procedures. Most were very likely or likely (30.4% 
34.8%, respectively) to routinely their IV drug 
of providers (69.6%) would nelJalltlS profile if the patient disclosed 
drugs. These findings are aware of health 
IV drug use, yet they about asking about 
However, when inquiring about of blood transfusion, only 39.1 % of the 
were somewhat likely to ask I-'''"L ..... '' • ., about a previous transfusion, suggesting 
an area where further education is ne~~aea. 
Survey questions pertaining to rpt~'rr~ 
.. ",,.,,,yt,,,,.rl that 67% of the reSPOlloe:ms were 
C treatment, 1 
of patients with hepatitis C (Table 1) 
or likely to refer I"UL1 ....... ., 
to patients for treatment. 
providers (47.8%) were very likely to encounter barriers in 
patients referred for treatment. respondents, 73.9% indicated they would 
very likely to refer patients to a C treatment clinic, while 8.6% 
they would only be somewhat likely or unlikely to to the hepatitis C clinic. 
is 
At the conclusion of the community assessment, healthcare were 
the opportunity to submit additional comments regarding specific to 
",VI,""", their patients treated for hepatitis 15 providers responded and 
lack of access to insurance, and 
psychological/social as to treatment. 
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1 
Community Assessment 
Item n Very Likely Likely Somewhat Unlikely 
n (%) n (%) Likely n (%) 
Questions Pertaining 
t6HCV 
Practices 
2. How likely are you to 23 7 (30.4) 8(34.8) 5 (21.7) 3 (13.0) 
ask a routine 
about a 
use? 
3. How are you to 23 16 (69.6) 2 (8.7) 2 (8.7) 3 
order a hepatitis 
should the 
patient disclose 
their use of IV 
4. How are you to 23 7 (30.4) 3 (l3.0) 9 I) 4 
ask a routine 
about their 
blood transfusions? 
5. How 22 5 (22.7) 5 (22.7) 4 (18.2) 8. (36.4) 
order a 
should the 
patient disclose a 
history of blood 
transfusion? 
Questions 
to Referrals 
6. How likely are you to 22 II (50.0) 6 (27.3) 1 (4.5) 4 (18.2) 
refer a for 
hepatitis C treatment? 
7. How likely are you to 23 II (47.8) 3 (13) 4 (17.4) 5 
encounter barriers in 
your 
referred for C 
treatment? 
23 17 4 (17.4) 1(43) 
clinic? 
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Hepatitis C Initiative Outcome Evaluation 
Rounds 
topic focused on 
Series was attc:mcled 49 providers on April 23, 2012 
where treatment of hepatitis Of those who 34 
completed the Hepatitis C Outcome 20 were primary care providers 
and were providers from Several minor '-''''''-''5'_'' were made 
to in attempt to the volume being 
seen by providers, obtain information on procedures, to identify those 
who adopt the suggested age-based screening 5UJ'Y"UH"v. A small was 
to one man to better how many were seen 
the to offer insight into provider to find adequate care as 
well as how many individuals be referred to hepatitis C clinic. those who 
submitted a survey, 23(67.6%) had seen 0-5 patients last year; 
within 
patients; 
stated they had seen patients; had seen 1 patients 
year; in that same time period, one provider (2.9%) had seen 21-30 HCV 
two (5.9) providers had seen over 30 individuals with 
are reported 2. 
was a wide responses when were asked 
a risk-based HCV assessment (question Once again, this indicates an area 
education might 
scn~enmg recommendation put 
inform primary care providers on the current HCV 
the U.S. ~r""""nt",h Services 
(2004). majority of providers (79.4%) would order a hepatitis profile if a 
disclosed risk(s) of acquiring a 
somewhat or unlikely to 
virus. Over 20% still reported they would be 
a hepatitis profile 
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patient disclosed Of the 
providers who completed survey, 67.6% reported they would likely or likely 
adopt age-based HCV screening recommendations. 
will should to of patients aware of the 
ultimately higher numbers of people referred to the clinic. 
Of the providers who attended the Grand Round would refer 
individuals for HCV treatment. Only 17.7% reported they would be somewhat or 
unlikely to refer patients HCV treatment. This indicates that at least some of the 
providers from other heaIthcare <;'Pt"1l1f'I'<;' would patients HCV treatment. 
Encountering barriers in getting patients referred for hepatitis C treatment 6) 
was reported in 55.9% of responders, .2% were somewhat likely or unlikely to 
encounter OJ" ...... "'. and one respondent, a urologist, did not answer the question. 
slightly Community Needs As:ses:smt~n where over 60% 
reported encountering ~ ...... u~'''; in getting their patients referred HCV 
treatment. Most importantly, 91.2% of providers surveyed the community-based 
hepatitis C clinic would facilitate the care for HCV patients. Ofthe two responders 
who reported HCV clinic would not facilitate care for their patients, one AU""U",.,,,,,,,, 
himself as a surgeon, the other was not a primary care provider. 
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2 
Outcomes 
n Likely Somewhat Unlikely 
n (%) n (%) n (%) 
Questions Pertaining 
toHCV 
Practices 
2. How likely are you to 
a hepatitis C 34 8 (23.5) 9 (26.5) 10 (29.4) 7 (20.6) 
Risk-Based 
Assessment? 
3. How are you to 34 22 (64.7) 5 (14.7) 3 (8.8) 4 (11.8) 
order a hepatitis 
should !.he 
patient disclose their 
risk(s) for C? 
34 13 (38.2) 10 (29.4) 6 (17.6) 5 (147) 
Questions 
to Referrals 
5. How likely are you 34 19 (55.9) 9 (26.5) 4 (11.8) 2 (5.9) 
to refer a patient for 
C treatment? 
6. How were you 33 8 (23.5) II (32.4) 5 (14.7) 9 (265) 
to encounter barriers 
your 
referred for 
33 22 (647) 9 (26.5) 0(0.0%) 2 (5.9) 
hepatitis treatment 
clinic facilitate your 
ability to care for your 
patients? 
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Data was further analyzed to better understand specific screening practices 
and referral issues for 
Survey. The majority 
in the previous 
local primary care providers who completed the Outcome 
care providers (70%) 
seen more than 6 ~'''''''H'''' 
seen hepatitis C p~"~u...., 
was a 
of responses when 
Of the primary care 
likely to perform 
performing a risk-based assessment (question 2). 
who responded, seven (35%) reported they would very 
screening; six (30%) would likely; six (30%) would 
somewhat likely; and one (5%) would be unlikely. helJatms profile would be very 
or likely "' .. "'A"'''-' 
acquiring a h .. ,,,,,l',,h 
90% of the primary care 
screening recommendations 
providers, 85% 
the 
HCV screening (question 
HCV treatment, 75% 
patient disclosed 
would adopt the aQc::-DaSf~Q 
Of the primary care 
surveyed encountered 
barriers to getting patIents referred. Lastly, 100% of the primary care providers reported 
community-based "",.."",.",., C treatment clinic would 
patients. 
Health Perception 
A total of 47 .. <>,.'3 ..... " were received at 
clinic between October 1, 11 
processed and seen for at 
were recent and were not 
..... r''''''''T completion. 17 
March 1 201 
one appointment. Many 
processed or scheduled 
reI,err::lls, 12 patients were 
the care for 
hepatitis C treatment 
17 patient referrals were 
", ........... 1'> 30 referrals 
pOllnnnents at the time of 
to participate in 
early program evaluation. Of the five who did not two lived out of the 
county, two had moderately severe mental illness, and one was ineligible for 
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treatment v,",,,,u, ... ,,,,, active alcohol two patients living out 
to participate U"'''',Q.U''''' .... "' ...... "','" and the other were 
OJ", ... ,«u"", they were deemed for treatment for various medical 
reasons. one of the 12 patients who in the early evaluation initially 
declined to the clinic one week to sign the consent. 
L>..I' .• V'.'~ participants, seven (58.3%) were .""uall'" while five (41.7%) were HA",.''''''', 
50 to 69 years old (M=57.75; Genotype 1 was .... ,..,,,,, ... t,,,,ri In 
one patient was rPr,n..,tpl"1 as genotype 3. 
program evaluation, ten were naYve to HCV treatment (never 
having had treatment previously), one (8.3%) was a and one (8.3%) was a 
of interest, two (16.7%) Nine (75%) patients lived in 
to the south, and one (8.3%) 
two required indirect .. "'1",' .... '" 
HH'''''HU'~ treatment; one patient was sent to 
lived in a 
the 12 
perceptions 
order in Table 3. In 
barriers to care, patients were asked to rank 
a rural county to the north. 
evaluation prior to 
one to gastroenterology. 
hepatitis C treatment are 
patients' perceptions of 
on a scale ofO-200mm 
using the very little, somewhat, and very much to guide their answers. 
two mlL1mneters equated to 1 %. Using the scale, IJU"",,'.;) who participated in the 
.. u. ......... "'.u had perceptions of having little overall control over the management 
of their 
was 
C at baseline. Of those, 
in managing their 
somewhat sure what was expected of them. 
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not 
other 25% felt only 
90% patients reported having 
inadequate resources to manage their hepatitis C. Only one patient felt they had adequate 
resources to manage their hepatitis C. Lack of adequate psychological/emotion support 
was perceived by 58.3% of patients, 33.2% perceived they had at least some support, and 
one patient felt adequately supported. When asked about support with decision making 
(question 4), less than half (41.7%) felt supported in making decisions about their 
hepatitis C care, 33.2% felt somewhat supported in making decisions about the HCV 
care, and 24.9% felt supported in making decisions about their HCV care. Lastly, over 
70% of patients at baseline perceived confidence in their ability to follow a prescribed 
hepatitis C treatment plan. 
Table 3 
Rank Ordering of Perceived Health Perceptions at Baseline 
Survey Question 
I. Felt in control over the 
management of your 
hepatitis C 
5. Understood what was 
expected of you in 
managing your hepatitis C 
2. Had adequate resources to 
manage your hepatitis C 
3. Had adequate 
psychological or 
emotional support 
4. Felt supported in making 
decisions regarding your 
hepatitis C 
6. Had confidence in 
yourself to follow a 
hepatitis C treatment 
regimen. 
Mean 
3.05 
13.6 
23.5 
24.9 
43.1 
74.7 
72 
Standard Deviation 
5.8 
21.3 
31.3 
31.9 
38.4 
37.2 
The limited number of patients in this evaluation prohibited a more 
sophisticated statistical However, a number were from these 
preliminary results. Of the 12 patIents who completed the first health perception 
nine patients progressed to a physician consultation and were to complete 
two. 4 summarizes change in mean scores and standard deviations of time one 
compared to time two Overall, ""':>'Ct"':>"""/1 barriers to hepatitis C 
treatment patients two. Patients' perceptions 
of having confidence in following a treatment plan 1 ...... ''''' ...... at high in both 
Improvements in mean scores occurred patients in perceptions of control 
of the management of their hepatitis C an mcreased mean of 
to How well they understood what was of them in managing their 
hepatitis C (question five), had an increased mean of 13.6 to a mean of 49.6. Patient's 
perceptions of having over the management of their hepatitis the lowest 
both survey one and two. 
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4 
1. Felt in control over 3.05 5.8 22.7 27.9 
the management of 
your hepatitis C 
2. Had 23.5 31.3 41.3 36.3 
resources to manage 
your hepatitis C 
5. Understood what was 13.6 21.3 49.6 40.1 
of you in 
your 
hepatitis C 
4. Felt supported in 43.1 38.4 57.7 38.3 
decisions 
your 
hepatitis C 
3. Had adequate 24.9 31.9 59.0 44.6 
psychological or 
emotional support 
6. Had confidence in 74.7 37.2 77.6 29.0 
follow a 
hepatitis C treatment 
Summary 
results of the provided preliminary 
infonnation on the physicians' perceptions the for improved healthcare 
services for individuals hepatitis C in area of interest. Of those responded, 
1 % would refer patients to the community hepatitis C clinic. Hepatitis C Initiative 
Outcome Survey showed that over 90% of providers surveyed felt the community 
hepatitis C clinic would ability to better care for patients with 
hepatitis Additionally, the Perception Survey showed improved scores of 
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health ",,,,,r"""r,J-, the one surveys as compared to from time 
two surveys. 
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This 
6 
DISCUSSION 
will further U1",","".,.;) the findings of this project highlight 
successes and challenges during development and implementation. 
project was to provide improved access and care individuals 
purpose 
hepatitis C in an 
underserved area. The was developed in phases including evaluation 
community need; development implementation of a community-based hepatitis C 
clinic; enactment of an evaluation plan; provider perceptions early ...... r.·l"M"<> 
outcomes. The ",H'.,..t", put developing and implementing this n,.r"",,'T 
individuals hepatitis C this community of and 
to treatment. improved health perceptions of patients rp(y",.,n.n 
The project required enormous support the Hepatitis C Initiative steering 
committee institutional leadership. Their support successfully motivated other 
providers to complete the Community HCV Needs Assessment and the 
Hepatitis C Initiative Outcome Survey. The of the provided the necessary 
validation local that improved care was nel~aea for individuals 
hepatitis C supported establishment of a hepatitis C 
to the provider's ability to care for hepatitis C patients. 
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The use ofthe chronic care model for this project provided a critical 
for the exploration of 
The CCM guided 
served as the ne,~essaI"Y 
were utilized for 
delivery support were 
provided 
hepatitis C clinic that 
informed patient. 
Provider Surveys 
and facilitators of hepatitis C care defined 
1-.. ,.,,1'1,,'''' ,.,,,,,.pnr provided a focus for program 
evaluation. While all of the components 
cornp(mems of self-management support 
VUJLUUL/5" that Df()m·ote:d successful outcomes. 
the healthcare system, 
interactions between a team 
A relatively small number of responses were received from the Community 
an 
Assessment and the limited .......... v'v. was attributed to the fact that surveys were ""u","",",y 
to all providers in health n..,.Tuln1r .... 
hepatitis C treatment. In retrosoe<:t. 
assessment to most 
of their potential to 
hepatitis C community 
helped to ensure a 
response. This may augmented by mailing reminder nn.,"tf',,,,.rI 
who had not yet responded or ",,,,.,,,,,n,,/,; a follow up email. In addition, the 
response time between the launch and deadline for replies may 
to 
responses rates. Yet, the 
from providers regarding the 
C Needs Assessment validated concerns 
services for their patients with 
C. The additional comments by providers at the end of the survey were u,,,./5,, .... and 
helped to catapult the 
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surveys attempted to identifY the patients who were seen by 
providers in the community. The response between the surveys; the 
of providers responded having seen C patients in their practice 
year. In retrospect, a zero value should added to the survey 
the opportunity to had not seen a hepatitis C patient 
the last year. The survey lack a true understanding of 
l.n .... ".A"'-' are seen by of interest. 
_,..., ___ ~ to screening procedures surveys showed varying 
pra,cnces among providers. To date, 
"''''A'~'''AAUAF> for HCV (US Preventative 
l':>J:'I.'-UQ.,.;:o\#U assessment remains the guideline for 
2004). It is widely rpn, ..... rt~'r1 
that only 25% of those infected with HCV are aware of their diagnosis. The current risk-
assessment is inadequately identifying individuals. Age-based screening 
presented as a viable alternative to screening and is reported to 
numbers of people aware diagnosis. The Grand Round '-''''~'''''''''' 
to pre:sellt age-based HCV 
majority of providers Qllr"p~,'Pri In'"'I'-''' .. ..,'''' would likely adopt the 
"'"."' ..... ,'u,,'''"' recommendations. If community providers, 
of individuals referred to C clinic can be expected. 
Generally, the surveys effectively a,;,Tt'lp,rpri needed information. more 1'",,..,,,,&>1'<,1'1 
survey for the Community would have yielded more optimal 
In regards to HCV screening, the validated inconsistencies in using 
assessments. To improve the care with hepatitis C, 
to be adopted. 
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Project Development and Implementation 
From the initiation of the hepatitis C project, evidence-based practice guided 
program development. However, defining program protocols and establishing adequate 
paper documentation consumed significant time in the early stages of program 
development. While initially this was a time concern, this early detail proved to be 
exceedingly valuable. Establishing the medical record for completeness and 
organizational flow was necessary prior to patients being scheduled at the clinic. 
Additionally, unanticipated challenges presented included designing coordinated clinic 
schedules; establishing efficient processing for patients during the work up phase of 
treatment; and reducing fragmentation of services. 
The unanticipated chaUenges ultimately affected the number of patients who were 
seen at the clinic during the project time period. Time constraints and the community 
announcement letter about the hepatitis clinic lead to several patient referrals not being 
processed by the project completion. Those individuals who were not seen for an 
appointment received a letter and were informed they would be contacted when 
permanent HCV clinic staff was secured. 
Program Evaluation 
Early program evaluation provided preliminary insights on patients' perceptions 
in navigating barriers to treatment. Although the sample size was limited, early data 
trends showed improvement of all health perception questions between survey one and 
survey two. Patients generally felt confident to follow a treatment regimen which may 
prove to be beneficial as they move through the stages of pretreatment work up and 
treatment initiation. Of the surveys collected from time one to time two, one previously 
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on all health perception questions. Because 
was the perception scores related to patients naIve to 
treatment. 
Limitations and Challenges 
Many this project. Some of the '-'U'U"'U5'~~ 
Dle:m~~ntmg this project may be unique to the ____ ,.., __ area 
For example, the location of this project was in a 
where most providers know each other. This 
project to move more steadily than in larger communities. The DNP was 
also known community and may have allowed collaborations that may not In 
other communities. 
project focus on the challenges in developing a new 
without a dedicated and sufficient technological support. In collaborative 
coordination of patient work-up and treatment ... '-"' .... 1">"' ... "'. 
autonomy for the DNP student in ordering laboratory 
and responding to testing 
two half days per week in addition to the nn""""~, 
month. Fortunately, 
physician DralctJc~ed in the clinic area weekdays managing infectious '."'''''''<4"" 
were 
project. 
was available to view the laboratory results of 
to the clinic. 
'-'v'vu ............... ' .... communication efforts improved steadily over the course 
as 
included 1'"P1",>,.,.<> notification, incoming telephone Ull:':l:l<:lgl;;:l, "',""YU' 
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was 
was 
"""'",VA .. appointments, faxed pharmaceutical res;pons€~s The DNP ':J<YU'-'"U was 
available by cell phone and responded to emails on days was not in the The 
ambulatory clinic nurse helped to coordinate HCV clinic 
student. In retlroS1Dec:t. this of staff <A"~""''''''',,,, should have encouraged 
throughout project to ensure a smooth 
"' .... , .... 114 not be secured by time of 
Implications 
ambulatory 
completion. 
should 
The of the ""'I,,""'lH'" C dilemma will be at its e:reate;st this U\;;\,QU'I:'. The 
of this increased preparedness a West H, ... ''"'U1f'» .... '''. community 
for the presumed increase HCV volume the new HCV screening recommendations 
are enacted. model of care and processes this project can be applied to other 
Using model in communities will require motivated, passionate 
individuals who can dedicate time and """,,,,.,.,,, to HCV program development. In sum, 
time period project ex(:ee(leC1 two years included a thorough literature 
review on 1U" ..... "'., of care HCV 1Tp",'tn1P""'t· completion a Community 
Assessment to assess provider concerns; development and implementation a 
community-based treatment and early 
Practice 
Involvement of a Doctor of Nursing Practice Student 
treatment ....... r'rrr"'rn evaluation. 
process of establishing a multidisciplinary approach to 
HCV treatment involved the coordination several members a healthcare team. 
the first project ua,,1V1., the DNP student thoroughly reviewed current 
literature on HCV models care and to treatment. An analysis of 
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infonnation was guided by incorporating components of the Chronic Model in 
a ",£u"nn,"p ... ,~n"'''p to care with the ''''''~'''1V'U'''' for 
improved outcomes. 
DNP student was liaison between administrative steering 
and partners, 1-''''' ........... and their 
the clinic support staff. In collaboration with the 
physician, the HCV treatment programming was developed and 
disease 
U,","'v,",. The DNP 
student provided HCV educational services to 1-'''''''''''''''' referred to the clinic and provided 
to the 
provided infonnation to 
in HCV treatment regimens. The 
manager on estimated community 
student 
clinic referral .,, .. " • ., .. HCV treatment regimens; and anticipated 
responsibilities of a nurse practitioner to coordinate HCV treatment This 
",,,,>AVA> was used to secure a temporary 
(Appendix R). 
Community Involvement 
oos:mcln at the 
project allowed 
collaborate and improve care 
.",,,,,,.,-,'uu.,,,, from a variety 
patients with a chronic health 
completion 
services to 
West 
This multidisciplinary approach to improving care for individuals with 
hepatitis C focused on the addressing common to successful treatment. 
the healthcare • ...,,,,,,,.v'u,,,.;> from nursmg, 
administration, pharmacy, mental health and ","""'V"V" servIces, vv"u ......... J agencies, 
public "V,,,,,,,, and finance. efforts in this community may offer '''V''b'''~ to other 
attempting to ",.''''''J1'''U similar improvement initiatives. 
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Association 
Advanced 
advocacy. 
this ~~ •• .u.HUJ.u. 
magnitude 
accomplished by 
Education 
this project, the DNP ,,, ........ ,," 
as outlined by the American 
(AACN) in the Essentials of Doctoral Education for 
2006). The core competencies focused on nnrn<lM 
scholarship, education, innovation, clinician, and 
to effectively treat individuals with hepatitis C in 
to bring stakeholders together and present 
as it existed. Translating current research into practice was 
itA,""f1,,,.A and adapting guidelines in the development of 
protocols for treatment. Advocating for appropriate clinic staffing and strong educational 
components to clinic programming was imperative. The potential impact this 
project 
In 
OP''lpr<ltp additional DNP practice innovations from this clinical site or 
Policy 
occurred during a time when the impact of 
"''''''70r! across the In 2010, the State of Michigan Hepatitis C 
investigation reviewing the dilemma 
rec:ontlmenClatlOils for greater screening, DfI::venWJn. treatment 
of C continues to expand, 
to decide how personnel and HU ........ J ........ resources are 
chronic illness. 
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to Macrosystem 
project addressed improving care for 
level. The efforts put forth during the 
scu.sSH)nSOnCOJllat)Or;atl()n with 
partnership 
Qualified Health 
treatment A ...... AY~l1 community practices and, +h"" .. .,+" .. .,. .. V .... "'TlI£1 
to a DOlten1UaJ ma,Cf()svstem level. 
31,2012 yet another meeting was held in this ""'.,, ........... y to SPt,C111Cal1 
bring local ___ ,,.._ ... __ C treating providers together to discuss the challenges 
the HCV treatment and the workload 
treatment. The meeting was attended by the DNP student, a family nurse 
disease physicians, the medical director of the who 
a gastroenterologist, and two physician 
onveI'sal1orls "",,,y.,,,,",u on to manage the increasing number of referrals 
and treatment and how the age-based screening might current 
.""F;u'V'Jv ..... with the virus, The 
",",<LLH;'''' individuals with HCV prohibits 
Treatment monitoring stnlteJl:les case 
as viable options to increase case loads. ..,.\,;'UH,.VIIUH 
this community may be augmented by 
use of Doximity, an on-line network established to allow 
the ""''''''',''1I''1"11n to A specific hepatitis C treatment group 
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for providers in this community to u""" .... ;>.:> challenges in HCV 
eventually, case study review is l.I!<lJ.lll',",U. 
Care Act 
At time of project completion, the clinic had not yet received a single referral 
a ",,,"'O~'T who lacked healthcare insurance. C is prevalent in 
I-'U"U.U\"'H~, it is likely that with mental illness, drug and/or 
not yet been <l('rpPtlPt1 or U''''I5H'V':>\.,Y 
l ...... "'Tn",. Court uphold the decision to mandate 
lJ"'lC1P~l1' Protection and Affordable 
:-"P.,.Vl("f'<l 2010) for all US I'.h'7o", 
accordance 
2010 (US Department of Health & 
1.I",",'I.I,v will flood the healthcare 
",,,,,,,r,,,",, with the potential to diagnose higher numbers of people with hepatitis C. The 
improved preparedness of this community to care for current and increasing numbers of 
with hepatitis C shows dedication to 
serious healthcare system 
nrl""Plnt time the outcomes 
healthcare relative to hepatitis C 
Act passes or fails. Impacts 
community in 
are unknown. 
occur regardless of whether 
C screening 
F'. """'V.lA"',,;) are pending and will require V .. ,,,"VA",,, evaluation of optimal 
of service delivery. How we advocate 
............ u.,~ a critical question for healthcare 
as a 
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or increase access to the 
and the healthcare industry 
Sustainability 
From the initiation of the institutional leaders had a clear understanding 
of community need to the inadequate care for individuals with C. 
Healthcare institutions have responsibilities to welfare the and 
therefore u"" ... ",,,,, this as a community initiative. Financial 
considerations for the hepatitis C clinic included billable services provider 
laboratory radiology services, hospital pharmaceuticals services. Prescription 
have OPn,Pr<> covered the cost of medications with submission of prior 
authorization documentation. pharmaceutical companies offer generous 
opportunities for those high deductibles and patient a.':'~'l':''''Ul\,''' are available 
be sought using the for with HU ... "' ... resources. Available grant opportunities 
preliminary data of patient volume, anticipated personnel required to manage case loads, 
projected UH ...... "~ .... ., to AU"U"C;" community-based hepatitis C clinic. 
Future Research 
The implementation of this community-based HCY treatment clinic generated the 
possibilities for and practice innovation projects. example, a study 
benefits of individuals with C participating a support and 
rates of successful treatment may 
""'I.""'''' project this community 
to increased numbers of local support groups. 
include evaluation HCY treatment 
outcomes collaborative efforts between a DNP prepared practice nurse and 
Lastly, one of biggest challenges in treating hepatitis Cis 
time U"'~U"H in monitoring laboratory ''''",.J.UF, Improvements in the efficiencies of 
monitoring may be augmented with use electronic registries 
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management of 
This would an exceptional VHU''"'V'''F.'"' in this setting where 
documentation still exists (Appendix S). 
Future of Nursing 
Adopting structural changes in education and supporting terminal np{lrpl~<! 
nursing ...... ""?,,~"" is in line with recommendation key messa.ges forth by 
Institute Medicine (10M, 2011) on Future of Nursing, Leading Change, Advancing 
Health. are poised to have a greater impact on the direct indirect 
U.4UV ... 'U healthcare. 
level of education and 
educating clinical and administrative nurses with the highest 
their of implementation science 
rigorous academic requirements, improved u'-'<uu • ..., ..... outcomes at costs are 
Additionally, collaborative between nurses, physicians, other 
healthcare professionals be encouraged and will hopefully lead to VHClLHr,'.'" 
healthcare ,",V""" • .;) and improved outcomes. 
Summary 
C is a major international dilemma occurs frequently 
populations who from other This hepatitis C initiative 
included an assessment community development and implementation 
''-'V-11'''''''''''.1 hepatitis C treatment program; evaluation progrrurnm,mg by 
health pel:ceIPW)nS pertaining to barriers to and nrr'''"1PFl early 
outcome evaluation. The community-based hepatitis C treatment clinic was 
with collaborative efforts by Hv • .lHJj,,,UJ." providers, institutional and community 
V.L~,"''''JlVUa..t., generating a multidisciplinary approach to "'"'If' ..... " ... ' C care. conceptual 
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framework of the Chronic 
eOllCaUOJn, support, and 
Model helped to focus 
between 
programming on patient 
long term outcomes this project will the preparedness 
Western Michigan for the impending impact hepatitis C this decade. 
implementation of 
care for their 1-' .... "' ....... 
.... ""·I"PlnTll'"<! of individuals 
C clinic allowed community providers access 
early program evaluation showed improved health 
C. 
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Appendices 
Appendix A 
Chronic Care Model 
Chronic Care Model 
The Chronic Care Model 
Resources and Policies 
Se]f-
Management 
Support 
Patient 
Delivery 
System 
Design 
Proactive 
Practice Team 
Improved Outcomes 
nc><I"",-d by The MacC",lIln.1il\J1>: 
ll.' ,\C1'·ASfM JournaL. and lIook. 
From "Chronic Disease Management: What Will It Take to Improve Care for Chronic 
Illness?" Wagner, E. H. 1998, Effective Clinical Practice, 1. Reprinted with permission 
(Appendix B) 
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DDt:nOJIX B 
Physicians Copyright 
American of Physicians Copyright Permission 
ACP 
J. U""'''.l''l'l'''1 CoLLEGE OF I-'uvc,,"', 
INTERNAL MEDICINE I Doctors 
June 12 
State 
1 Campus 
Allendale, MI 49401-9403 
Dear Leigh; 
Thank you for your request to print (dissertation) 
WAECP121 
following from TUh"""'" Clinical I-'>'",r","o 
1, Effective Clinical 1998, Vol1, Chronic Disease Management: What Will It Take 
rnn,rr'l\,'''' Care for Chronic Illness? Wagner EH 
Permission is granted to print preceding material with the understanding that you will 
appropriate credit to Effective Clinical Practice as original source of the material. Any 
version must carry a disclaimer that the American of Physicians is not 
the accuracy translation. permission grants non-exclusive, worldwide 
edition in print for not profit only. not grant permission 
entire articles or unless explicit is given. 
letter represents the agreement between ACP and Elaine Leigh, MSN, FNP-BC for request 
17568 and all prior terms the requestor. 
Thank you for your interest in Annals ofInternal Medicine. If you have any further or 
would to discuss the matter further, please contact me at or fax 856-489-4449. 
Coordinator 
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Appendix C 
Multidisciplinary Model of for Hepatitis C 
Multidisciplinary Model of Care for Hepatitis C 
Institution 
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Hepatitis C Initiative Introductory Letter 
Hepatitis C Initiative Introductory Letter 
February 2011 
Colleague(s), you know: 
Hepatitis C (HCV) is the most common blood-borne infection in the United 
States and is the leading cause of liver disease according to National 
Institutes of Health. 
The Centers of Disease Control and prevention estimates that 3.2 million people 
are affected with HCV within the US. The number of new cases is declining, 
but the total number of deaths is expected to rise in the next 20 years due to 
prevalent cases with long-standing infection. 
Chronic hepatitis C accountsfor 8,000-10,000 deaths per year. 
Over 700 Chronic Hepatitis C cases have been reported to the Muskegon 
County Health Department since 2006. 
,.H"'",,"''-' to announce a new community healthcare A 
with support of community leaders to improve the care 
This is forward through collaborative 
doctoral student on the development a multidisciplinary hepatitis C 
treatment program. Ms Leigh is currently completing Doctoral of Nursing Practice 
(DNP) at Grand Valley State University and brings years 
gastroenterology and hepatitis treatment. Her to 
a sustainable program access to treatment 
assist 
those with 
hepatitis C. 
Barriers to treatment will be modified by partners practice. Psychological 
case management, pharmaceutical support, patient education support 
programs will included 
We your help. Assessing your opinion of the magnitude of issue will assist in 
early project development. You are encouraged to complete the survey by clicking on 
the link or copy and paste the address into your web browser to Survey Monkey by 
March 11,2011. 
All information will bottom the we are collecting 
names of providers and practices to ensure we collect an appropriate representative 
from your area. 
Thank In <;>r1,'g.Yu ..... for your support initiative. 
92 
Appendix E 
C Needs 
Hepatitis C Assessment 
Thank you for your willingness to this It is important that each provider in 
the practice fill out a ror,,,r,,.,1-L> survey. 
Please answer the questions in numerical order 
Please identify specific barriers you have encountered in getting your patients referred for 
1. How many hepatitis C patients have you 
assessed/diagnosed in the last 
o O-S 
o 6-10 
o 11-20 
o 21-30 
o >30 
2. How are you to a routine patient about 
a history of intravenous (IV) drug use? 
o likely 
o Likely 
IJ Somewhat likely 
o Never 
3. How 
should 
o Very likely 
o likely 
o Somewhat likely 
o Unlikely 
4. How likely are you to ask a routine patient about 
a history of blood transfusion? 
likely 
o 
o Somewhat likely 
o Unlikely 
hepatitis C 
Name person who the 
Name 
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S. How likely are you to 
profile should they 
blood transfusion? 
o Very likely 
o likely 
o Somewhat likely 
o Unlikely 
a hepatitis 
history of 
6. How likely are you to a patient 
hepatitis C ,. .. ""',.nn""n 
o Very Likely 
o Likely 
o Somewhat unlikely 
o Unlikely 
7. How likely are you to encounter 
barriers in getting your patients referred 
C t"rO:l1"YY,,,, 
o Very likely 
o Likely 
o Somewhat 
o Unlikely 
8. How likely is it for you to refer patients 
to a dedicated, multidisciplinary hepatitis 
C treatment clinic in Muskegon? 
Very likely 
o likely 
o Somewhat likely 
o Unlikely 
Appendix F 
Hepatitis C Initiative Stakeholder Meeting Invitation 
Hepatitis C Initiative Stakeholder Meeting Invitation 
April 1,2011 
I am to ask you to participate in a collaborative community healthcare initiative to 
improve outcomes and patients C. are developing a 
mUltidisciplinary treatment program to better serve patients in our area and we are seeking your 
opinion. As you there are numerous biopsychosocial caring 
people with hepatitis and treatment programs can be labor for the patient and 
healthcare providers. program two specific goals. to access to treatment 
and also to improve therapy outcomes instituting a collaborative evidenced-based 
We are developing a taskforce of professionals to further discuss magnitude health 
dilemma posed by hepatitis C in our community by reviewing of a recent Hepatitis C 
Needs Assessment from primary care providers in our area. Ultimately we are 
individuals who are interested in assisting with the coordination of services to better serve 
patients with C. interested in part of this program development or 
overall feedback or comments this please join us at 7:00am on Friday April 
2011 (location undisclosed). 
Thank you in advance for your support of this community healthcare initiative. 
Respectfully Submitted, 
Committee 
Hepatitis C Initiative 
94 
Appendix 
Multidisciplinary Partnerships 
Multidisciplinary 
Partner 
Infectious Disease 
Physician 
Care Provider 
Psychological 
Pharmaceutical Support 
Social Work/Case 
management 
Ophthalmologist! 
GynecologicalJ 
Obstetrician 
Radiologist! 
Pathologist 
Multidisciplinary Partnerships 
Institutional! 
Community 
Referral 
Institutional 
Institutional 
Community 
Community 
Both 
Community 
Community 
Institutional 
Community 
Reason For Consultation 
Provides the initial health 
assessment, orders 
pretreatment laboratory studies, and 
HCY education. 
Determines for physician 
consultation. 
Provides final clearance for patient 
to initiate C treatment. 
This will evaluation of all 
pretreatment and referral 
consultations. 
Provides on-going healthcare 
management of individual's 
health and chronic illnesses. 
Psychological evaluation for 
stability of mental illness 
Evaluation for onI2-to~ar 
patient assistance 
programs, authorization 
requirements, and educational 
materials 
Evaluation for health insurance or 
financial barriers to 
treatment 
Evaluation of ocular and visual 
stability, for those with 
Contraception Management 
(Ribavirin is a Pregnancy category 3 
which females to adhere to 
sex practices 
estro en forms 
Provides and evaluates liver imaging 
and liver These results 
determine the course of 
treatment 
Evaluation for stability of history of 
coronary artery disease or kidney 
disease 
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Continuation of Care 
APN will on-
going management of 
hepatitis C treatment once 
patient is deemed 
for treatment 
RN will ongoing 
of medication 
side effects and laboratory 
schedules. 
Collaboration with APN 
on treatment progress. 
Col.laboration with HCY 
treatment team to manage 
medication side effects 
For moderate to severe 
mental illness, continuous 
documentation 
trans 
Follow up care 
for any visual 
durin treatment 
pregnancy tests 
for all female patient on 
treatment who are 
of reproduction 
exams as necessary 
May require pretreatment 
electrocardiogram gram 
and/or echocardio ram 
Appendix H 
Informed Consent 
Infonned Consent 
Study Title: Evaluation of a Community-Based Hepatitis C Treatment Program 
Program Evaluator: Elaine A. Leigh 
Introduction 
You have been asked for pennission to look at your medical record. Before you decide 
to agree or not agree, or not to volunteer, we want you to know as much as possible about 
this project. The U. S. federal government expects us to provide this infonned consent 
paper to you and you will be asked to sign it. Please read it carefully and talk to the 
investigator, Elaine A. Leigh, if you have any questions about the study. You may also 
want to talk about it with your family or friends. 
There are general ideas that apply to all project involving people done at Mercy Health 
Partners: 
1. Taking part in the project is entirely up to you. This means that you do not 
have to be involved in the project if you don't want to. 
2. If you agree to give consent for us the review your medical record, and then 
change your mind, you can ask us to stop. There is no penalty for this. 
3. You may not gain any benefit in taking part in the project. However, we may 
learn more about hepatitis C treatment programs from you, and this may help 
others in the future. 
Has this project been approved by the hospital? 
Yes. The project has been reviewed and approved by the IRB at Mercy Health Partners. 
The members of the IRB are physicians, other healthcare professionals and community 
members. They volunteer their time and expertise in reviewing all projects done at Mercy 
Health Partners. Because the program evaluator is a graduate student, Grand Valley State 
University's Human Research Review Committee (HRRC) has also approved the study. 
Why was I asked to be included in this project? 
You were asked to be in the project because you have been evaluated at the hepatitis C 
clinic. We are asking all patients who have been seen at the clinic between October 1, 
2001 and March 15, 2012 for consent to look at their medical records since they have 
been at the clinic. 
What is the purpose of the project? 
The purpose of this project is to complete an initial program evaluation of the hepatitis C 
treatment program started at Hackley Hospital in Muskegon Michigan. 
What do I have to do to be part of the project? 
This project requires your pennission to review your medical records. Once you have 
read the consent, had your questions answered, you will be asked to sign this from. 
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What is the duration of the project? 
When data has collected reported from those patients who their 
consent, the complete. 
What are the risks and discomforts? 
There are no known health risks for those who to in this project. To keep your 
data private, it will be copied to another form without your name, address, or 
personal information that could identify you. 
What are the benefits of being part of this project? 
There are no known to you being a part of this project, but clinic and 
nurses will learn more about services they to you. It may help them find out if 
the hepatitis C treatment program is meeting patients' needs. This information may 
shared with other nurses and doctors programs like this one. 
What are my rights and responsibilities? 
if you agree to give access to your medical records this project, you may 
to have your information removed later by calling evaluator, 
Who wiU see my records and how will they be kept confidential? 
Only those people who work on the project will see any record could identify you. 
No one will give out name or personal information. Information you us will 
added to information from other people the project before it is reported in public. No 
public reports will use your name, address, or other personal data that could be linked to 
you. You will to Portability and Accountability Act 
(HIPAA) form with your consent to allow the program to review your 
information. A will be used to further protect your data. 
Also, as part of routine projects, members of the Mercy Health 
.,."'Tr"A'"" Institutional Review Board (IRB) contact you about your experience with 
this study. 
What are financial responsibilities? 
is no monetary or cost for of this nrr\1 ".,~t 
If I take part in this project, can I also participate in other project/studies? 
''''H_~U.'''' to take part this project does not you joining other 
If I don't want to be in the project any more, what should I do? 
You are to leave the project at any time. decide to leave the project, there is no 
penalty. If you decide to leave the project, all you have to do is contact the program 
evaluator listed at the of this 
Could I be taken out of the project even if I want to continue to participate? 
are some reasons why you could be taken out of the project, although 
unlikely, the project for some reason could be suspended or cancelled. 
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Who can I contact for more information about this project? 
The names and contact information program IS 
contact her if want to: 
411 more questions 
411 Obtain more information about project 
411 Discuss concerns project you have 
411 Stop participating before it is finished 
A. Leigh, MSN, FNP-BC 
Hepatitis C Program Evaluator 
Doctor of Nursing Student 
Grand State University 
301 Michigan St. Rapids, MI 49503 
(616) 331-5694 
Who else can I contact if I have any concerns about the study? 
Ruth Brintnall, AOCN, CHPN, APRN-BC 
Student Advisor 
Kirkhof College of Nursing 
Valley University 
301 au''-''li/:;, ...... NE, .. ,. .... v,'"'" MI 49503 
(616) 331-3338 
You 
If you any questions about your as a partICIpant this project contact: 
Valley State University Human ",."".,""..... Review Committee at (616) 331-3197. 
Health Institutional Review at (231) 672-3941. 
I understand that by agreeing to in this I am responsible for informing 
the program evaluator of any concerns. 
I have had a chance to ask questions about the project and was given enough time to 
make a decision about being part of the project. I have talked to as many as I 
need to me make decision. I understand that my participation is voluntary. I 
have a copy this form willingly agree to participate in project. 
Signature 
Witness U'5HUL.u 
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Appendix I 
Health Perception Survey 
Health ~P'·""Pl ... hr\n 
Directions: In order to best meet your needs, please respond to each of the following statements 
marking an (X) on the Line that best corresponds to your educational needs in the two weeks. Knowing 
your needs will assist clinic staff in offering appropriate resources as you complete treatment for hepatitis 
C. 
==~::;.:. How well do you understand the disease of hepatitis C? an (X) near the VERY 
LITILE would indicate you do not understand the disease of hepatitis C. You can mark the line anywhere 
along the line. 
When thinking about the past two place an eX) on the line below each statement to identify 
the degree to which you: I L Felt in control over the management of your hepatitis e 
I I 
10 5~ 
VERY SOMEWHAT 
LITTLE 
2. Had appropriate resources to manage your h .• ""d'+" e 
1 I 
I I 
0 50% 
VERY SOMEWHAT 
! LITTLE 
3. Had adequate psychological/emotional support 
I I 
I I 
0 50% 
VERY SOMEWHAT 
LITTLE 
4. Felt supported in making decisions about your hepatitis e care 
I I 
10 I 50% 
VERY SOMEWHAT 
LITTLE 
5. Understood what is expected of you in managing your hepatitis e 
I I 
10 5~% 
VERY SOMEWHAT 
LITTLE 
6. Had confidence in to follow a HeV treatment plan 
99 
I 
100~ 
VERY 
MUCH 
I 
I 
100% 
VERY 
MUCH 
J 
I 
100% 
VERY 
MUCH 
I 
I 
100% 
VERY 
MUCH 
I 
I 
VERY 
MUCH 
OOt:nOllX J 
Patient Information Handout 
Patient Infonnation Handout 
the 
You are here to treatment for hepatitis We developed a nn\HT'''Tn 
to you the treatment. Many of you may know 
treatment for hepatitis C can be challenging but we are here to support Be 
aware that not everyone who is evaluated will eligible treatment. We carefully 
detennine treatment eligibility on a one-to-one basis as everyone a different 
background. 
of our new program we are you to complete a short at 
beginning of some of visits to clinic. program is focused on providing you 
with the education and support to your while you are going through 
treatment. The survey questions allow us to detennine which areas we can provide 
further to you. 
You will not be required to write anything; however, you will be asked to simply 
an "X" when answering the questions. Your surveys will remain as of your medical 
record and therefore confidentiaL 
Hepatitis C 
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AppendixK 
Informed Consent Narrative 
Informed Consent Narrative 
My name is and I am a part of the office team here at hepatitis clinic. I 
would to invite to a study we are doing at clinic to evaluate our 
~ .... "_ .. ". We want to learn more about our patients who are enrolled at clinic 
including think about common that may impact your treatment. We are 
inviting all who come to the clinic. Is it okay I continue? 
First, participation is voluntary. You will not benefit directly from 
participating in study but what is learned may help you or someone study 
will not require any additional work from The study will use information already 
your medical like surveys have completed already. it will 
that us your permission to allow an investigator, who is a Doctor of Nursing 
Practice student at to access your medical records. The investigator will collect 
information such as your your type of C, and county of residence. 
Your name will not or used anywhere ... as a matter of your 
will be as it is collected to fully protect you. will an opportunity to ask 
me and you can call the investigator I cannot answer your questions. We 
want you to your consent carefully you decide. consent will have 
addition information about the study. Do you have now? 
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Institutional Board Valley University 
DATE: 
TO: 
FROM: 
STUDY TITLE: 
REFERENCE #: 
SUBMISSION TYPE: 
ACTION: 
EFFECTIVE DATE: 
REVIEW TYPE: 
@) 
GRAND VALLEY 
SrATElJNJvERSITY. 
www.gv>o.edu 
February 15. 2012 
"'Iaine Leigh, MSN 
Grand Valley State University Human Research Review Committee 
[282940-2] Evaluation of a Community-Based Hepatitis C Treatment Program 
12-82-H 
Revision 
APPROVED 
February 15, 2012 
Exempt Review 
Thank you for your submlsslon of materials for thi$ research study. The Human Research Review 
Committee has reviewed your submission and approved your research plan application under Exempt 
review. category 1-2 and 1-4. This approval is based on no greater than minimal risk to research 
participants. All research must be conducted in accordance with this approved submission. 
Pleas. insert the following sentence into your Information/coosent documents as appropriate. All 
project materials produced for participants or the public must contain this information. 
Th/$ EXEMPT research protocol has been approved by the Human Research Review 
Committee at Grand Valley State University. FUe No. 12-82-H. 
Exempt protocols do not reqvira formal renewal. However, we do confirm on an annual basis that the 
research continues to meet the criteria for exemption and that there have been no signiflCBllt changes 
in activity or key personnel. By February 15, 2013. please complete the brief C<>ntinulng Review 
AppliCJItion Fenn. available In your IRaNet Project Designer, or from our website, ~.gvsu . edufhrrc. 
and submit this form via IRaNet. 
Once study enrollment and data analysis have been conduded, please complete the Closed Protocol 
Reporting Fonn on our website, and upload a saved copy to IRaNel. 
This project remains subject to the research ethics standards of HRRC policies and procedures pertaining 
to exempt studies. 
Please note the following in order to comply with federal regulations and HRRC poUcy: 
1. Any revision to previously approved materials must be approved by this office prior to initiation. 
Please use the Change in Protocol forms for this procedure. This includes. but is not limited to. 
changes in key personnel, study location, participant selection process, etc. 
2. All UNEXPECTED PROBLEMS and SERIOUS ADVERSE EVENTS to participants or other parties 
affected by the research must be reported to this office within two days of the event occurrence. 
Please use the UP/SAE Report form. 
- 1 -
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3. All instances of non-<:Oll1pjiance or complaints regarding tIlis study must be reported to tIlis office in 
a timely manner. There are no specifIC fonns for this report type. 
It you have any questions, please contact the HRRC Office, Monday through Thursday, at (616) 331-3197 
orhrrc@qvsu.edu. The office observes all university hondays, and does not process applications during 
exam week or between academic !eons. Please include your study title and reference number in aU 
correspondence with tIlis office. 
cc: 
- 2-
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Appendix M 
Institutional Review Board Mercy Health Partners 
(f, MERCY HEALTH PARTNERS 
Elaine A. Leigh MSN, FNP-BC 
15306 Forest Park Dr. 
Grand Haven, M149417 
Dear Ms. Leigh, 
February 16, 2012 
The MHP IRB has reviewed your project entitled, Evaluation of a 
Community-Based Hepatitis C Treatment Program. Specifically the following 
documents were reviewed: 
• Written plan for the evaluation 
• Hepatitis C Treatment Program Evaluation Tool. 
• Informed Consent Narrative 
• Informed Consent Document 
This project is exempt from IRB oversight, based on a design which 
involves a retrospective review of existing data, and a plan for securing protected 
health information. Further reports to the MHP IRB are not required. 
Thank you for your submisSion, and please contact me if you have any 
questions or concerns. 
~SHoke ,....u~: •..•...•• 
f. ...--..V... ••• 
n .!. stot9,Street · ," 
Shelby, MI 491.S5 " 
23 1.861.21 !l<i 
Kathleen Thomas, RN, MSN 
MHP IRB Representative 
: ~ •.• :.; ·:'M?RCY·cAMpus;: ";.:.:::, '~:. ;~iJ~;~;~~ c.yd~~. ';.. t 
i SOO:E. s..eUnan BNd. ' P.O. eo. sis .:; • • l7ail. 00Jc ~, p.e. ~ JSS ' o' 
Mo$lo>gon. MI49443.~~· . • t.\uil«oQon. M1 ~9443.1»5a '. • •• • 
23l.\S72.2000 . (600) S63.41~5 - .231,1,'2:2000 ' 1800/ 3".4125 
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AppendixN 
Hepatitis C Treatment ....... ' ..... "', .. Tool 
Birth date/age 
Gender 
Male/Female 
In the previous 
2 weeks have: 
2mm=l% 
Question I 
Felt in control over the 
management of your 
hepatitis e 
Question 2 
Had appropriate 
resources to manage 
your hepatitis e 
Question 3 
Had adequate 
psychologicall 
emotional support 
Question 4 
Felt supported in 
making decisions 
about your hepatitis e 
care 
Question 5 
Understood what is 
expected of you in 
managing your 
hepatitis e 
Question 6 
Had confidence in 
yourself to follow a 
HeV treatment plan 
Hepatitis C Treatment Program Evaluation Tool 
____ (Patient Code) 
DemographicsiHistory 
Genotype 
lor 4/2 or 3 
Residential County 
ea erceptlon H lth P S urvey 
Date Date Date 
(8aseline/educa (Consultation) (Start of 
tion session) Treatment) 
-
mm=_% 
-
mm= % 
-
mm=_% 
-
mm=_% 
-
mm= % 
-
mm=_% 
-
mm= % 
-
mm=_% 
-
mm=_% 
-
mm= % 
-
mm=_% 
-
mm=_% 
-
mm=_% 
-
mm= % 
-
mm=_% 
mm=_% mm=_ % 
-
mm=_ % 
-
-
105 
Treatment history 
Naive/Partial Responder/Relapser 
Community Referral: Yes/No 
Agency: 
Date Date 
(First follow up) (Second 
follow up) 
-
mm= _% 
-
mm=_% 
-
mm= % 
-
mm=_% 
-
mm= % 
-
mm=_ % 
-
mm=_% 
-
mm=_% 
mm=_% 
-
-
mm=_% 
-
mm= % 
-
mm=_% 
Appendix 0 
C and Correspondences 
Hepatitis C Clinic Documentation and Correspondence 
Hepatitis C Pretesting Requirements 
Date Test Normal Results 
Hepatitis C Genotype 
VIRAL LOAD Undetected 
CBC w/Diff 3.8-10.8 WBC 
12-16/37-47 HGB/HCT 
150-450 PLT 
CMP 74-106 GLU 
7-20/0.7-1.2 BUN/CR 
15-46/15-46 AST/ALT 
TSH 0.47-4.68 
Uric acid 2.5-6.6 
Triglycerides 5-150 
Iron studies 37-170 Serum Iron 
265-497 TIBC 
15-50 %Sat 
6.2-264 Ferritin 
Protime/INR 11-13sec 
Pregnancy (when applicable) 
Anti Nuclear Antibody (ANA) Neg 
Anti Smooth Muscle Antibody Neg 
(ASMA) 
Ceruloplasmin 16-45.0 
Alphafetoprotein (AFP) <6.0 
Hepatitis B surface antibody Absent 
(HBVsAB) 
Hepatitis A antibodies (HAVAB) Neg 
HIV 1/2 Neg 
Eye exam 
EKG (when application) 
Imaging (CT, Ultrasound) 
Liver biopsy 
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Hepatitis C Clinic Intake Assessment 
Name: 
Birth date: 
State: 
Approx of diagnosis: 
HCVRNA: 
Liver 
Previously treated: 
Tolerated? 
Imaging: 
YIN 
YIN Bipolar 
YIN Schizophrenia 
YIN Currently medicated 
YIN counseling 
YIN Suicidal thoughts/attempts 
Pharmacy: 
Support person phone: 
Past 
YIN DM 
YIN 
YIN CAD 
YIN 
YIN COPD 
YIN Other(s): 
Medication list 
LastE eExam: 
YIN Alcohol: 
YIN Recreational 
YIN Tobacco: 
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use: 
Risk factors 
YIN IV use 
YIN Blood before 1992 
YIN Tattoo, 
i YIN 
wlHCV 
exposure to someone 
YIN 
YIN Married 
Lives with: 
Working hours: 
Sleeping 
Source of support: 
Social 
Relative Contraindication 
YIN < 10, ANC <1000, PLTs<50 
YIN Hemodialysis <50 
YIN Substance and alcohol use 
YIN Anticipated Poor compliance 
YIN Untreated mental health disorder 
YIN Stable auto-immune disease 
Con trace tion 
YIN Sterilization procedure: 
Hysterectomy (fubruligation/V asectomy 
YIN Regular menstrual cycles 
LMP: 
Current birth control: 
YIN Menopause LMP: 
Vaccinations 
YIN Hepatitis B Virus (HBV) 
YIN Hepatitis A Virus (HA V) 
Seasonal 
YIN Pneumonia 
Absolute Contraindication 
YIN Uncontrolled, active, major psychiatric 
(encephalopathy, coagulopathy, ascites) 
YIN uncontrolled medical disease 
(DM, CAD, TB, Cancer) 
YIN Untreated thyroid disease 
YIN Thalassemia and sickle anemia YIN Pregnancy, nursing, child-bearing potential 
YIN Sarcoidosis 
For HIV co-infected: 
CD4<200 or 
Concurrent use if Zidovudine 
(ZDV) i 
(anticipated no birth control) 
YIN Active, autoimmune disease 
YIN HIV co-infected 
108 
Advanced uncontrolled HIV (CD4 
<100) 
use "'Ull"""',,, (ddl) 
Symptoms: 
YIN Asymptomatic 
YIN Fatigue 
YIN Anorexia 
YIN Myalgia 
YIN Arthalgias 
YIN Asthenia 
Clinical Presentation 
Signs: 
Skin: 
YIN 
YIN 
Spider angiomas 
Porpheria cutanea tarda 
Stigmata of cirrhosis: 
YIN Mild jaundice 
YIN Hepatomegaly 
YIN Splenomegaly 
YIN Peripheral edema 
YIN Hemorrhoids 
End Stage Liver Disease (Decompensated) 
YIN Ascites 
YIN Weight loss (except where ascites) YIN Encephalopathy 
YIN Coagulopathy (PT >3sec; INR > 1.3) 
YIN Varices (bleeding or non-bleeding) 
Childs- Pugh 
The score employs five clinical measures of liver disease. Each measure is scored 1-3, with 3 indicating 
most severe derangement. 
Measure 1 2 points 3 points , Patient Valu point 
.. " 
Date 
-
" 
Total bilirubin, Jlmolll <34 34-50 (2-3) >50 (>3) (mgldl) «2) 
Serum albumin, gil >35 28-35 <28 
PTlNR <1.7 l.71-2.20 > 2.20 
Ascites None Mild Severe 
Grade III-
Hepatic None Grade I-II (or suppressed IV 
encephalopathy with medication) (or 
refractory) 
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HEPATITIS C THERAPY CONSENT 
Contraception 
D For patients receiving pegylated interferonlribavirinltelaprevir (Incivek) therapy 
____________ am aware that ribavirin, one of the oral components of Hepatitis C 
therapy, can cause birth defects. Defects can be caused if either the mother or the father is using this 
medication. 
• I realize if I become pregnant, or impregnate someone, the resulting child could have 
birth defects. 
• I agree to use two forms of birth control during my therapy and for 6 months 
afteIVIards. 
• If I am female, I may be required to obtain negative pregnancy test prior to starting 
therapy. 
• If I am female I may be required to submit to monthly pregnancy tests for the duration of 
my therapy and for six months after therapy is fmished. 
• I agree to advise the clinic if either I or my partner fail to use appropriate contraceptive or 
suspect a pregnancy may have occurred despite the use of contraceptives. I understand 
that oral contraceptive may not be as effective while I am on treatment. 
Some examples of non-hormonal forms of birth control are: a male condom with spermicidal jelly or 
female condom with spermicidal jelly; a diaphragm with spermicidal jelly, a cervical cap with spermicidal 
jelly, or an intrauterine device (IUD). 
___ (patient initials) 
D For patients receiving pegylated interferonlribavirin therapy 
____________ am aware that ribavirin, the oral component of Hepatitis C therapy, can 
cause birth defects. Defects can be caused if either the mother or the father is using this medication. 
• I realize if I become pregnant, or impregnate someone, the resulting child could have 
birth defects. 
• I agree to use two forms of birth control during my therapy and for 6 months 
afteIVIards. 
• If I am female, I may be required to obtain negative pregnancy test prior to starting 
therapy. 
• If I am female I may be required to submit to monthly pregnancy tests for the duration of 
my therapy and for six months after therapy is fmished. 
• I agree to advise the clinic if either I or my partner fail to use appropriate contraceptive or 
suspect a pregnancy may have occurred despite the use of contraceptives. I understand 
that oral contraceptive may not be as effective while I am on treatment. 
___ (patient initials) 
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• I understand Hepatitis C therapy can have side effects such as rlpr,,·poo' 
• I agree to notify my immediately have symptoms of severe aeiDreSSI'OI 
",,, ..... F,,,,,, or plans. 
• At the time, I do ( ), do not ( ), have a history or current =rnnT{\m 
psychiatric disorders. 
or suicidal 
de[)re1;sicm or 
• If I have a history of depression or any psychiatric disorders, I may be required to have clearance 
by my for treatment 
• If I have a history of depression or any psychiatric I may be required to be monitored by 
my the entire treatment. 
• I understand that C therapy can cause a decrease in certain blood and for this 
reason, frequent blood tests will be necessary. 
• I understand the importance of: 
o Regularly scheduled appointments 
o Blood work needs to be done in a timely manner and when requested 
o Monthly pregnancy test (where applicable) 
o the medication as 
o Reporting any ;:'''/'',5''''''''' V"~U'E>'N in my medications by any provider 
• I understand that my treatment may be cancelled ifl do not comply with these 
initials) 
I have been informed or and understand the risks and benefits of Hepatitis C therapy. I hereby request to 
Hepatitis C therapy. 
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Hepatitis C Clinic Referral 
Whom it May Concern, 
This note is to you know we have received a written referral from your healthcare 
provider for you to be seen at the hepatitis C treatment clinic. this time, we are 
processing referrals and scheduling appointments but because ofthe complexity of 
treatment we have a limited number of people we can see. We will be contacting you for 
an when we are 
We encourage you be as educated as possible about hepatitis C before your appointment. 
Additional education materials will be given to you when you are seen but in the 
meantime a good website for gaining infonnation 
We appreciate your patience, 
Hepatitis C Treatment Team 
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Medication Reconciliation 
Date Medications Needs Date Reconciled 
Reviewed Reconciliation 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
YIN 
Date Allergies Reaction 
NKMA O 
Date Signature(s) Initials 
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Requisition Hepatitis C 
Patient Information 
Name: 
Physician Information: 
XXX 
----------------------------
XXXIXXX 
Co to: 
Last 
Date Ordered: 
Routine Testing: 
0 Complete Blood Count w/diff 
(CBC) 
0 Hepatitis C RNA Quant 
(HCVRNAQ) 
0 Hepatic Function Panel (HFP) 
M F 
**Diagnosis reqnired** 
ICD-9 Diagnosis 
Chronic hepatitis C virus without 
hepatic coma 
Results Will be by location 
other labs fax to XXX-XXX-XXXX 
Other: 
o C genotype (HCVG) 
B Surface antibody 
(HBVSAB) 
o Hepatitis B Surface Antigen 
(HBVAG) 
0 Comprehensive Metabolic Profile o Hepatitis A Antibodies (HAAR) 
(CMP) o Smooth Muscle Antibody 
0 Thyroid Stimulating (ASMA) 
(TSH) Anti Nuclear Antibody (ANA) 
0 Pro time (PT)/INR o Ceruloplasmin (CERUL) 
0 Iron Panel (IP) o Alphafetoprotein (AFP) 
0 (FER) o HIV YS: Antibody screen mV1I2AS 
0 Uric Acid (URIC) o Other: 
0 Triglycerides (TRIG) Other: 
0 Creatinine (CRE) o Other: 
0 Chorionic Gonadotropin 
(HCG) Serum 
0 Human Chorionic Gonadotropin 
(HCG) Urine 
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Common Medication 
Lab Work 
Lab work is an important part of your chronic hepatitis C virus (HCV) therapy. Before and during 
treatment, your doctor will do blood tests. These tests will check for side and also tell you early on 
how well treatment is and how long you need to be on it. These tests may include a complete 
blood count viral load test, panel, and liver function tests. You must stick to your lab 
schedule because it is an of your treatment for HCV. 
Anemia 
In your blood are red blood cells. Red Blood cells carry oxygen. is needed throughout the for 
your muscles and organs to work properly. If your red blood cell counts become very low, you may have a 
condition called anemia. Your healthcare provider (HCP) will check your red blood cell counts 
periodically. 
Anemia is measured with a simple blood test. The blood test may show the amount of hemoglobin in a 
blood sample. The blood test may also report the hematocrit- the amount of red blood cells in a blood 
sample. Both values help to inform your HCP on the severity of anemia. 
The normal levels for these blood tests are different in men and women. For women, a normal lab value for 
hemoglobin is> 12 and a normal hematocrit is > 36%. For men normal lab value for hemoglobin is > 
13 gldL and a normal hemocrit is > 39. 
Nutrition 
It is important to maintain nutrition while on chronic C therapy to help provide your body 
with the nutrients it needs. Your medical plan should include healthy food and drink choices and moderate 
exercise. Exercise not only you build muscles, it also helps your body fight off illness and it can 
improve your mood and your "IJIJ":;"""'. 
Taste Alteration 
During treatment for you may notice that food tastes different. This is called UYO • .,"',J:>ta 
GOOZ-ee-a), or taste alteration. Food may taste different or it can taste bad. There are things that you can 
do that may make this easier to live with. After you are done with you should notice that your 
sense of taste returns in about 2 to 12 weeks. 
Flu-like Symptoms: General Information 
Many people feel like they have the flu after they take their chronic C medicine. You may have a 
fever, a headache, and muscle aches that start several hours or days after treatment. Some of these 
symptoms (fever, may lessen after a few weeks as your body used to the medicine. 
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Flu-like Symptoms: Headaches 
You may get headaches when you start treatment for chromc hepatitis C. They often start in the first 4 to 8 
hours after treatment. Your headaches may lessen after a few weeks, once your body gets used to the 
treatment. 
First, it is important to understand what things can lead to headaches. You may get headaches after not 
drinking enough water, not eating enough, stress, sleep problems, or too much or too little caffeine. There 
are also some medical conditions that can lead to headaches, such as history of migraines, high blood 
pressure, dental problems/jaw pain, allergies, sinus infection, and other problems. Talk to your healthcare 
provider (HCP) about what may lead to your headaches and what you can do to manage them. 
Nausea 
You may feel "sick to the stomach", "queasy", or have an "upset stomach". This is called nausea. It can 
happen because you are taking chronic hepatitis C medication or because of the chronic hepatitis C itself. 
You may also have more saliva (spit); dizziness; light-headedness; trouble swallowing; cold, clammy skin; 
and a fast heart rate. You may feel the worst during the first month or so of treatment, while the body gets 
used to the medication. 
Nausea is one of the common side effects of chronic hepatitis C therapy. Ask your HCP for a complete list 
of side effects. 
Nausea is different for everyone. You might be a little queasy or you may feel very sick. Talk to your HCP 
if this feeling doesn't allow you to do things you do every day or if it is hard to take your treatment. 
Nausea can come from other things like stress, headaches, other viruses or bacteria, alcoholic beverages, or 
eating too little or too much. Figuring out things that bring on your nausea can help you and your HCP 
control it. Some easy steps can make a big difference in how you feel. 
Fatigue 
People being treated for chromc hepatitis C often feel tired (also known as fatigued). In fact, 65% of people 
said that they felt fatigued while being treated for chronic hepatitis C. If you are fatigued, you may feel 
tired, weak, worn out, and unable to get out of bed. Also, you may not feel like doing anything, even the 
things you once enjoyed, and you may feel down. You may notice these feelings getting worse throughout 
the day. Fatigue may also be a symptom of depression. Talk to your healthcare provider (HCP) about your 
fatigue and if you think you may be depressed. 
It may help to know that you are not alone - many people with chronic hepatitis C also experience fatigue. 
Of course, it is important to talk to your HCP about how much energy you have. That way, he or she can 
give you ways to help. 
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Date 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Problem 
I Problem Recommendations Date Resolved 
Common Side 
Effects 
Itching/Rash 
Insomnia 
Fatigue 
Rectal discomfort 
Poor 
appetite/Nausea 
Taste Alteration 
Muscle aches 
irritability 
Hair thinning 
(see effect 
management 
# below) 
Management Suggestions 
apply hydrocortisone as needed, 
Bedtime routines, avoid caffeine in the evenings, warm 
showers, low 
Conserve energy, rest periods during day 
Keep area clean and dry, apply OTC hydrocortisone as n",,~r .. ::.n 
Small meal portions, anti-nausea medications as prescribed, 
ginger hard candies. 
Y2 banana or chocolate may help, avoid metal utensils 
Tylenol (limit to <2000mg/day), drink plenty of fluids, 
stress 
symptoms, take medications as prescribed, 
activities (reading, music, low impact .'",,,,'rn',," 
I Sideofeff,ect of medication, nothing can be done to slow 
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i 
i 
BIOPSY INSTRUCTIONS 
Time: Appointment 
--------------------------- ----------------------
PRE-BIOPSY INSTRUCTIONS 
1. Arrive 10-15 minutes 
the necessary paperwork 
home. 
2. Do not take any or 
week before biopsy. 
your appointment time, provided that you have completed 
signed consent 
cornalnmg aspirin 48-hours or preferably one 
3. Please us of any significant bleeding history or clotting problems you 
observed. Our radiologist will review your blood tests (PT, PTT) to ensure normalcy. 
Tbis test must be performed witbin six (6) montbs of your biopsy_ If you bave bad 
tbis test done witbin six montbs, please tell our staff where and wben it was done. If 
not, you win to bave tbis test done before your biopsy. 
4. Assume a diet between 2-4 hours prior to biopsy and 
diet for 2 hours prior to the biopsy. 
5. For dependent diabetICS: 
a. If eating usual diet 
b. If is only 
breakfast, take usual insulin 
liquids: hold a.m. T".,.r_"r·., 
intermediate or long-acting insulin dose. 
CARE AFTER LIVER BIOPSY 
instructions are recommended as safeguard against 
Please follow them 
1. As desired 
only a liquid 
take usual a.m. 
2. If you nausea, all food 1 hour then start with liquids. Progress to 
"""'An<>t""i'i drinks should be full liquids, then a light bland diet, then a regular Any 
room temperature. 
3. the local wears you may pain and soreness. Occasionally, you 
may experience referred in your neck and/or right shoulder. If you need medication 
you may take acetaminophen products as or ibuprofen 
products such as Advil, Nuprin, Motrin, etc. Do not take aspirin 24 to 48 hours. 
4. your biopsy, remainder of the day. next day you may return to work or 
other light activities if they do not involve lifting or straining. A void strenuous 
for 48 hours: runnmg, lifting, 
5. If you experience excessive bleeding or pain at the headed ness or 
heartbeat upon standing, or 
the C treatment clinic at (213) 728-1887. 
6. Your doctor will the pathology results in approximately 7 days and or she will 
them you. 
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Exam Letter 
Dear Doctor: 
We would like to thank you for our patient an ophthalmologic exam. He/she is 
scheduled to begin treatment with pegylated interferon for chronic hepatitis C infection. 
with has associated: 
.. Retinal or vein thrombosis 
.. Retinal hemorrhages 
.. Cotton-wool spots 
.. neuritis 
.. Papilledema. 
jJ,",,,':U-l",", of this, that all patients an examination 
at baseline. Furthermore, the FDA that with pre-existing 
ophthalmologic disorders (e.g. diabetic or hypersensitive retinopathy) should also TP£"PH'P 
periodic ophthalmologist exams during their interferon alpha treatment. 
.. there are pre-existing ophthalmologic findings? 
o Recommend exam at three (3) month until the completion 
of treatment (this can range from 24-48 weeks). 
.. If you do not problems 
o Recommend exam if changes in vision are reported 
If you have any questions or comments, free to contact us at .. >J .... ,,~-.. >-L 
We would appreciate a faxed ophthalmology evaluation to XXX-XXX-XXXX. 
Hepatitis C Care 
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Care Provider 
PATIENT:~ _____ _ 
Hepatitis C 
Healthcare Provider: 
We are currently your patient for hepatitis C treatment. on the patients 
HCV genotype, the treatment course will require up to 48 weeks. These 
medications potentially cause a wide range of side effects. 
There are certain 
on treatment. 
____ . The patient 
we ,."",."'''''''T you to do to patient prior to going 
a psychiatric or by a psychiatrist. 
a dilated exam to that he/she 
no 1-' .... ''-'fiL..,.'' .. F, retmc'Datnv as this treatment can eX~lcelrbate that. 
__ 3. The patient would 
would be able to 
artery \.&1",,",,,,.,,", 
__ 4. The patient must 
to have a cardiac to be certain that hislher 
anemia conditions and not pre-existing coronary 
all alcohol and illicit for at least six months. 
nearly 40% 
L./"":v..>. 1999) and leads to rapid 
Hepatitis 
disease 
admitting to 
with alcoholic liver 
UJfJrrlf'.,rll oJliver fibrosis in 
per day oj alcohol 1999) 
5. We would co-morbid stabilized, this includes 
such as diabetes, hypertension, and thyroid "",,,'"''''''''...,. 
has chronic pain issues, to be monitored closely 
VAU,,,",,",,",, prior to going on hepatitis C treatment. 
If the marked have been will undergo final 
for hepatitis C treatment pegylated Int~·rtprnn 
... ,.",'tA·''''''''' inhibitor for known genotype 1. 
evaluation to rI",lr"'1"1"" 
ribavirin, and aU .... HJ'VU,UU 
therapy is initiated, 
scheduled visits to 
are checked frequently and is monitored by 
If you have any this regard, please do not u,",~." ... ,.,", to call. 
Sincerely, Hepatitis C Team 
120 
Re: 
Dear 
C Education .... '-'.;,.""',,, 
C Care Team 
understand 
C Education Session 
you to attend an \"' ......... " ... VllUI .">'-' ",."> ".n I which 
risks for HUJll"'I.'U.;).;)IVU 
include discussions on medical treatment 
HCV treatment. and monitoring 
The next class will be held on _________ at ______ am/pm in the 
clinic "",nTp.,."",,,,,, room on x:xxx 
We ", ... ,.",,,~ .... ,,,,,, you to bring a AU"" .. AV'"'' or a friend along with 
you any questions, to 
C Team 
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Psychological Referral Letter 
Mental Provider: 
above mentioned patient is being for treatment of Hepatitis C with 
pegylated interferon ribavirin. The treatment is rigorous and difficult. One of the 
major effects medication is an increase in depression, anxiety, irritability, 
occasionally an increase in pain. 
We 
they 
in who psychiatric as as 
active healthcare providers to whom they can tum additional help as 
well as social support. team would you to this to 
the stress for up to 48 weeks. In addition, we would to work 
with your patient to formulate a plan care that probable increased contact with 
a for period of Please fax the psychiatric clearance to: XXX-XXX-
xxxx 
We your assistance. If you any questions, please free to 
contact our support staff at: XXX -XXX -XXXX 
Sincerely, 
Hepatitis C Team 
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HCV Clinic No Response 
Date 
--------
Hepatitis C Treatment Clinic Referral 
Dear 
a from pnmary care 
to schedule you an appointment. At your appointment we will be gathering basic 
health and providing you on hepatitis 
We attempted to contact your by phone and been unsuccessful in scheduling 
this appointment. If you are interested in scheduling this initial session please XXX-
We encourage you bring a family member or a friend with you. 
Hepatitis C Care 
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Appendix P 
ne]:lal111S C realm em Clinic Announcement 
Date: 
To: 
From: 
SUbject: 
Hepatitis C Treatment Clinic Announcement Letter 
2,2012 
Medical Staff 
Medical Infection Prevention & Control 
Chief Medical Officer 
Hepatitis C Clinic 
We are in the process of establishing a Hepatitis C Clinic at the Ambulatory Infusion Center. We have 
to see a few to a better idea what the work load will be to better establish staffing 
.rprnpn,t<! as we gear up for numbers of patients. To get a better of idea of those anticipated 
numbers, we would request that you fax any referrals. 
At the time of referral, please send us a recent history and physical with an up to date medication list. 
Please have an ultrasound or CT scan of the liver done in the 12 months prior to the referral and also 
have the following lab work done within of the referral: 
• Complete Blood Count w/diff (CBCD) 
• Hepatitis C RNA Quant (HCVQRNA) 
• Comprehensive Metabolic Profile (CMP) 
• Protime (PT)/INR 
• Iron Panel (lBCPRO) and Ferritin 
Also, the following: 
• Hepatitis C genotype (HCVG) - once only, no time frame 
• HIV 1/2 Antibody Screen (HIV1/2AS) - within 12 months 
Please manage the expectations of the patients you send us regarding: 
I) Timeliness oj appointments. We have a limited capacity to see and treat patients at this time, 
although we expect that to change when we increase """".nu,,,, 
2) Likelihood ojreceiving treatment. There are significant number of contraindications and relative 
contraindications to treatment and thus not all patients will be candidates for it at the time of 
referral. 
• 
6 months 
uncontrolled 
transplant 
be "hc'hnpnt 
or other conditions known to be exacerbated by interferon or ribavirin 
disease 
• Severe concurrent disease such as severe hypertension, heart failure, coronary 
artery poorly controlled obstructive disease 
• Known hypersensitivity to drugs used to treat HCV. 
3) Treatment can be difficult, both because of their requirements for very high level of compliance 
with the medications combined with the fact that have significant side effects. 
UpToDate has a number of good review articles on this subject, 
1) Overview of the management of chronic hepatitis C virus infection 
2) Patient selection for antiviral for chronic hepatitis C virus infection 
3) Patient information, both basic and beyond the basics 
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ppelJQlX Q 
Hepatitis C Initiative Outcome 
."'v' ........... C Initiative Outcome Survey 
Additional 
1. How many 
o 0 
o 11-20 
o -30 
o >30 
2. How likely are you to ",,,,, .. T,.,,..,rn 
hepatitis C "' ..... ,,"'-.... ," .. ,_'" a~sse~ssrrlenr! 
o 
o 
3. How likely are 
profile 
hepatitis 
OVery 
o Likely 
o Somewhat 
o Unlikely 
4. How likely are 
i Based C 
i 0 Very likely 
o Likely 
o Somewhat 
o 
Comments: 
Thank you for your 
5. How likely are you to refer a paIllem for 
hepatitis C treatment? 
o Very Likely 
o Likely 
o Somewhat unlikely 
o Unlikely 
6. How likely were you to encounter 
in getting your patients .. ",T'''' .... ~'rI 
C treatment? 
o Very likely 
o Likely 
o Somewhat likely 
o Unlikel 
7. How likely will the community 
hepatitis C treatment clinic your 
ability to care for your 
o Very likely 
o Likely 
o Somewhat likely 
o Unlikely 
8. 
0 You are currently 
prImary care 
0 You are currently ma 
specialty 
0 
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Appendix R 
Pictorial the Hepatitis C Initiative Timeline 
Pictorial of the Hepatitis C Initiative Timeline 
2002-2008 
Sow the Seeds of Innovation 
July 2010 
Institutional Taskforce Meeting 
(DNP student as Educator) 
April 2011 
Community Taskforce Meeting 
(DNP student as leadership) 
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February 2010 HCV Steering Committee 
(DNP student as Advocate) 
July 20lO-April 2011 
Community Needs Assessment and 
Literature Review 
(DNP student as Scholar) 
October 2011 
Program Implementation 
(DNP student as Clinician) 
Appendix S 
Pictorial of the Hepatitis C Initiative Future Research 
Pictorial of the Hepatitis C Initiative Future Research 
April 2012 Project Completion 
(DNP opportunities for future research) 
127 
References 
References 
Abou-Saleh, M. T., & S. (2008). Prevalence and of hepatitis C in drug 
users: A Disorders Their Treatment, 7, 190-197. 
M., (2006). Impact a designated hepatology nurse on clinical course and 
quality of life patients treated with Rebetron therapy chronic hepatitis 
Gastroenterology Nursing, 149-155. 
Alfi'andre, Gardenier, Federman, A., McGinn, (2009). Hepatitis C in an 
urban cohort: Who's not being treClLtea Journal oj Health Care Jor the Poor & 
Underserved, 20, 1 078. 
AI-Saden P. c., McPartlin, F., Daly-Gawenda, Connor, J. B., & "-,,,,,,-,un.<.I., G. (1 
Hepatitis dilemma. American Association oj Occupational 
Health Nurses Journal, 47, 
American Association "-'v •• ~ .... ~" of Nurses (2006). The '-'''''''"'HJlU • .:> doctoral education 
advanced nursing practice. from 
American Liver Foundation (2007). Annual report. 
L., HlUllY. E. P., McQuillan, M., Kuhnert, W. L., & Alter, 
M. J. (2006). The <+1'-';1l'-''-' of C virus infection United States, 
1999 through 2002. Annals oj Internal 144, 705-715. 
128 
Kalishman, S., Thornton, K., 
..... rl'.Ufn J., Komaromy, M .. , 
Murata, G., Deming, 
Bankhurst, A., Katzman, 
Cosgrove, W. (2010). '-''''',p •. UJ'Y''''5 access to h",..."",hf'.", 
treatment-extension for outcomes (ECHO) project: 
innovation in specialty care. Hepatology, 1124-1133. 
Thornton, K., Murata, G., ........ ' ...... "', P., Kalishman, S., Dion, et al. 
(2011). Outcomes of treatment for C virus infection by primary care 
physicians. The New England Journal 364,2199-2207 . 
.LJ""uv, V., Baldovin, T., Trivello, R., A., (2008). Epidemiology 
U"""",,"LA,VU. Current Pharmaceutical 1646-1654. 
Ciliegi, P., Chiodera, A., na(;OSl Baldelli, F., et (2009). 
Peginterferon plus ribavirin for chronic C in opiate addicts on 
methadonelbuprenorphine therapy. Digestive and Liver 
303-307. 
McGovern, B., Dhar, R., K., Scheib,R., & Snydman, 
(2001). Increasing mortality due to "''''"'-'''"'''''''''' liver disease 
immunodeficiency virus Infectious Diseases, 
Caldwell, L., Stafford-Fox, 
Combination interferon 
& Benson, L., (2004). 
the treatment of 
Nursing implications. Gastroenterology Nursing, 55-62 
129 
Birkhead, G. S., Klein, J., A. R., O'Connell, D. Rothman, J. R., 
Feldman,L et al. (2007). Integrating mUltiple programme and policy 
approaches to hepatitis C prevention and care for injection users: A 
approach. International Journal on Policy, 18, 4 
Blackard, J. Yang, Y, Bordoni, P., Sherman, K. E., Chung, C. (2004). Hepatitis 
C virus (HCV) diversity in HIV-HCV coinfected subjects initiating highly 
antirectroviral theraphy. of Infectious Disease, 189, 1472-1481. 
Bodenheimer, Lorig, Holman, H., Grumbach, (2002). Patient self-
management chronic ,.u""",u..;,,,", in primary care. The Journal of the American 
Medical Association, 2469-2475. 
Bodenheimer, T., Wagner, H., & Grumbach, K. (2002). Improving care for 
with chronic illness. Journal for the American Medical Association, 288, 1 
1779. 
Brok, J., Gluud, L., Gluud, c. (2010). Meta-analysis: Ribavirin plus interferon vs. 
interferon monotherapy for chromc hepatitis C-an updated Cochrane review. 
Pharmacology and Therapeutics, 32,840-850 
Butt, (2008). in context of hepatitis C: L-OlrlCepr analysis. Journal of 
Advanced Nursing, 712-724. 
Butt, G., ""<l1'"""c·n ... B. & McGuinness, (2007). with the stigma of 
hepatitis Western Journal of Nursing J{e:~earcn 30, 204-221. 
C. Everett Koop Institute 12). Hepatitis an epidemic anyone. from 
130 
Centers for Disease Control (2008). Retrieved from 
http://www.cdc.gov/hepatitis/Statistics/index.htm 
Centers for Disease Control (2011). Retrieved from 
http://www.cdc.gov/hepatitisIHCVIHCVfaq.htm#section2 
Centers for Disease Control (2012). http://www.cdc.gov/hepatitisIHCVIHCVfaq.htm#d4 
Cheng W. (2010). Pros and cons of working with a nurse practitioner. Transplant Journal 
of Australia, 19,6-9. 
Choo, Q. L., Kuo, A. J., Weiner, L. R., Overby, D. W., & Houghton, M. 
(1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral 
hepatitis genome. Science, 244, 359-362. 
Chronic Care Model (2010). Retrieved from 
http://www.improvingchroniccare.orglindex.php?p=The_Chronic_ 
Care Models&s=2 
Clark C. H., & Ghalib, R. H. (1999). Hepatitis C: Role of the advanced practice nurse. 
American Association of Critical Care Nurses Clinical Issues, 10, 455-463. 
Coopey, M., Nix, M. P., & Clancy, C. M. (2006). Translating research into evidence-
based nursing practice and evaluating effectiveness. Journal of Care Quality, 21, 
195-202. 
Cotler, S., J., Wartelle, C. F., Larson, A. M., Gretch, D. R., Jensen, D. M., & CaritherJr, 
R. L. (2000). Pretreatment symptoms and dosing regimen predict side-effects of 
interferon therapy for hepatitis C. Journal of Viral Hepatitis, 7,211-217. 
Community Research Institute. (2010) retrieved from: 
http://www.cridata.orglGeoProfile.aspx?type=4&loc=26121 
131 
Crone, & Gabriel, M. (2003). C for 
Risks, scn~emlng. therapy 
complications. Journal of Psychiatric Practice, 10. 
(1999). C and .... "' ..... a'"" •• Journal of Hepatoiogy, 113-118. 
Dictionary.com (2011). from: h!!JW~l!Q!@D~:tSmm£~;:mJL 
Dolder, N. M., Wilhardt, M. & Morreale, A. P. (2002). Justifying a multidisciplinary 
high-intensity hepatitis C clinic by using decision analysis. American Journal of 
Health-System Pharmacy, 59, 867-871. 
Ehsani, J.P., Vu, & Karvelas, (2006). Exploring the need hepatology nurses 
and allied health professionals in Victorian liver Australian Health 
30,211 18. 
Harrison, Joyner, B., Safe, A. (2004). Providing treatment for C 
in an Australian rl1<'+"'£'T centre. Postgraduate Medical Journal, 80, 180-182. 
Flamm, L. (2003). Chronic hepatitis C virus infection. Journal American 
Medical Association, 289,2413-2417. 
Fahey, (2007). Developing a nursing for hepatitis Nursing 
Standard, 21, 
Ford, J. A., Cheong-Lee, (2007). The of hepatology nurse in the 
treat hepatitis C population. Canadian Journal of Gastroenterology, 
& Treloar, (2006). Spoiled identity in hepatitis C The binary logic 
of aeS1PaIr Critical Public Health, 110. 
132 
M. W., Shindo, M., Fong, Fox, C., Hoffnagle, J. H., Bisceglie, A. M. 
(1 Absence of hepatitis C virus from saliva semen with 
chronic hepatitis Gastroenterology, 102, 1 1308. 
Garcyia-Retortillo, M. (2011). Multidisciplinary program best traditional method HCV 
treatment. Presented at the 2011 Annual American Association for the Study of 
Abstract retrieved from 
htlp://www.infectiousdiseasenews.comlview.aspx?rid=893 35#jump 
Neushotz, & O'Connor-Moore, N. (2007). Medical/psychiatric 
nurse in chronic hepatitis C treatment: A case 
study. Archives of Psychiatric Nursing, 21, 87-90. 
Garrard, Choudary, V., Groom, Dieperink, Willenbring, M. L., Durfee, J. et 
al. (2006). mana~;emlent of hepatitis C: ofa 
CME program. Journal of Continuing Education in the Health Professions, 26, 
145-1 
Geppart, C. M. A., & (2005). Ethical the treatment of hp...,,,,,1",1", C. 
Clinical Gastroenterology and Hepato[ogy, 937-944. 
Ghany, M. G., Nelson, D. R., D. & L. B (2011). 
update on treatment genotype 1 chronic hepatitis C infection: 2011 practice 
guideline by the for study of liver Hepatology, 
54, 1 
Ghany, M. Strader, D. Thomas, D. 
management, and treatment of hp .... "'1"'1", 
1374. 
133 
Seeff, B. (2009). Diagnosis, 
C: Hepato[ogy, 49, 1335-
'-JUlL .. .:>. R. T., Williams, K. A, Carter, M. W., Spencer, M., & Solovieva, (2005). 
Perceived barriers to healthcare access among rural older adults: A qualitative 
study. The Journal of Rural Health, 12, 206-213. 
Grebely Genoway, Khara, M., LTUCllv'C:U Viljoen, M., Elliott, D., J.D., 
DeVlaming, & Conway, (2007). Treatment uptake and outcomes among 
current and former injection drug users directly observed therapy within 
a multidisciplinary model for treatment of 
The International Journal of Drug Policy, 18, 
Grebely, 1., Knight, Genoway, K. Vijoen, M., Khara, M., 
Optimizing assessment and treatment for h"",,,,, .. ,.h,, C virus 
C 
D., et aL (2010). 
illicit drug 
users: A model incorporating multidisciplinary care and support. 
European Journal of Gastroenterology & Hepatology, 22,270-277. 
A,& (2009). O'M'<'''~'' of treatment in hepatitis 
implications for nurse specialist practice. Australian Journal of Advanced 
Nursing, 27, 
Grogan, Timmins, (2010). Patients' perceptions information 
received from nurse specialist HCV treatment. Journal of Clinical 
Nursing, 19,2869-2878. 
Guadagnino, V., Trotta, M. P., Montesano, F., Babudieri, S., Armignacco, 
0., J., Maio, Monarca, R., Antinori, A (2007). Effectiveness of a 
multi-disciplinary standardized management model the treatment of chronic 
hepatitis C 
423-431. 
addicts engaged in detoxification programmes. Addiction, 102, 
134 
Hamilton, H. Gordon, C., Nelson, M., & Kerbleski, M. (2006). 
Physicians, non-physician ne,lltnlcru:e providers, patients communicating in 
Gastroenterology Nursing, 364-370. 
Hamlyn, A., (2005). Hepatitis Tackling silent epidemic. British Journal oj 
Hospital Medicine, 66, 579-582. 
Healthy People 2020 retrieved www.healthvpeople.govlhp2020 
Herrera, J. & Roveda, K. P. (1999). Update on managing hepatitis C: _'_I:Y'~ 
How to "V'-'~AALA# at-risk while therapy can 
still Journal oj Critical Illness, 14, 444-451. 
Hill, W. Butt, Alvarez, M., Krajden, M. (2008). Capacity enhancement 
hepatitis C virus treatment through .... ~',..,._ 
Journal oJ Gastroenterology, 22, 
Ho, B., Groessl, Dollarhide, A., Robinson, 
community-based care. 
D., Dieperink, (2008). 
Management of chronic neplatl11S C in veterans: The potential integrated care 
models. The American Journal oJGastroenterology, 103, 1810-1823. 
Holcomb, S. (2008). Caring for a patient with chronic l'"'IJ':tUU 
32-37. 
Hopwood, M., & Southgate, E. (2003). Living 
Critical Public Health, 13,251 
C. Nursing. 
Hopwood, M., & Treloar, C. (2007). Pretreatment preparation and management of 
Interferon based therapy hepatitis C virus infection. Journal oj Advanced 
Nursing, 59,248-254. 
135 
Institute of Medicine. (2011). Future of nursing, leading change, advancing 
Retrieved from !!.!:.!:~:...!.!...:::!...!.!~~~~~~~~~~~.!:.!:!!.~C£!.~~~ 
10hn-Baptiste, Varenbut, M., Lingley, M., Nedd-Roderique, Teplin, D., 
Tomlinson, G., et al. (2009). Treatment hepatitis C infection for current or 
former substance abusers in a cornmum Journal of Viral 
557-567. 
16, 
Johnson, R. W., & Holman-Speight, T. (2005). Nurse practitioner/physician assistant 
education and the management of 
Journal, 16, 60-62. 
Association of Black Nursing Faculty 
Johnston, & Fineout-Overholt, E. (2005). Teaching EBP: from zero to one. 
Moving from recognizing and admitting uncertainties to asking searchable, 
questions. Worldviews on Evidenced-Based 2, 98-102. 
Koff, R. S. (2001). 
setting goals. 
management programs for hepatitis C: A team approach to 
IIn~rH'V Management & Health Outcomes, 9, 1-439. 
Knott, A, Dieperink, M. D., Willenbring, M. S., J. M., Wingert, M., 
10hnson, 1. R., Thuras, & Ho, B. (2006). Integrated psychiatric/medical 
care in a chronic hepatitis C clinic: on antiviral treatment 
outcomes. American Journal of Gastroenterology, 101, £.-<...J"'r-k.£.'u£.. 
136 
Kontorinis, N., Young, B. Mac Quillan, G. De 
Chapman, M. (2003). Outcome, 
tolerability and v'-"" ....... of ,-,AVA"""" use nt",riprnn ribavirin for 
h",,.,,,,+itic C infection a shared care hospital clinic. Internal Medicine Journal, 
33,500-504. 
Larrey, D., Ribard, Boutet, 0., V., Niang, B., Pageaux, G. 
Vaucher, Arpurt, J. Boulay, Karlova, N., & J. P. (2011). 
Education by a nurse [t;:::;PO]!l:::;t; of patients with chromc "'''''~'''T''T. 
therapy with peginterferon-a2a and ribavirin. Clinical Gastroenterology-
Hepatology, 9, 781-785. 
,-,,",,-fA''''', N.E. (2002). The ....... ""0."0 treatment-associated 
in patients with hepatitis Gastroenterology Nursing, 25,201-203. 
Cto 
p,N'rpt,rp R. Williams, L., Pace, W., Fry-Johnson, Y., Pathak, K, 
et (2009). Context of clinical care: The case hepatitis C under served 
commumties-a report from care multiethnic network (PRIME net) 
consortium. Journal of the American Board of Family Medicine, 22,638-646. 
Lewis, M., Allen, H., & Warr, 1. (2010). development and implementation a 
nurse-led hepatitis C protocol for people with serious mental health problems. 
Journal of Psychiatric Mental Health NurSing, 17, 651-656. 
McEvoy, P., La,~au<;;;, S. (2008). Patient registries: central component of chromc 
care model. British Journal of Community Nursing, 
137 
McGarry, L. J., Pawar, V. S., Rubin, J.L., Davis, Younossi, 
Capretta, J. O'Grady, M. & Weinstein, M.C., (2011). Economic model of a 
birth cohort screening program for hepatitis c virus. Retrieved from 
hhttp://onlinelibrary.wiley.com.ezproxy.gvsu.eduldoill 0.1 0021hep.2551 O/pdf 
Merriam-Webster Dictionary, 2011, from: =~..:..:...::..;:....:.!..!.="-"==""-
webster.comldictionary/interdisciplinary 
Michigan ),::o""",rtrr,,::on1" of Community Health (2010). VAE'l11""'A summary: Hepatitis C 
advisory task force final report. (in press). 
Mistler, L. Brunette, M. Marsh, Vidaver, M., Luckoor, Rosenberg, 
S. D., (2006). Hepatitis C treatment for people with severe mental illness. 
Psychosomatics, 93-1 
Moore, G. Hawley, A., Bradley, (2007). Hepatitis C-studying ..,,,F,u ..... 
Gastroenterology Nursing, 346-352. 
National Digestive Information Clearinghouse (2010) rpTrH""'''£1 from 
National Health and Nutritional .... '"'.''', ............ ~ •• v .. Survey (1998). Retrieved from 
ftp:l/ftp.cdc.gov/publHealth_ StatisticsINCHS/nhanes/nhanes3/1 Oalreadme.txt 
National Institutes Health (2002) retrieved from 
http://consensus.nih.gov/2002/2002HepatitisC2002116htmLhtm 
P., & Cheng, W. (2008). Innovative practice in 
management of chronic hepatitis c: Introducing the nurse practitioner modeL 
Australian Journal of Advanced Nursing, 107-113. 
138 
Nyamathi, M., Dixon, Robbins, W., Smith, C., Wiley, D., Leake, B., Longshore, 
& L. (2002). Risk factors for hepatitis C virus infection among 
homeless adults. Journal of General Internal Medicine, 17, 134-143. 
Olson, M. & Jacobson, L M. (2011). Role the nurse practitioner the management of 
patients with chromc 
Practitioners, 23,410-420. 
C. Journal of the American Academy of Nurse 
Oprea, Braunack-Mayer, A., Rogers, W. A., & Stocks, (2009). An ethical 
justification for the chronic care model (CCM). Health Expectations, 13, 55-64. 
D. (2006). Using a simply patient to improve your chronic care. 
Retrieved from http://www.aatp.org/fj:nn/2006/0400/p47.html 
Palepu, Cheng, D. M., Kim, Nunes, D., Vidaver, Alperen, J., Saitz, & 
Samet, J. H. (2006). Substance treatment and rpt""',nt specialty care 
among persons coinfected with HIV /HCV who have alcohol problems. Journal of 
Substance Abuse Treatment, 411 17. 
Paterson, B. Backmund, M., (2007). 
stigmatization in about International Journal of Drug Policy, 
18,364-373. 
Pincus, H. A., Page, A. K., Druss, Applebaum, P. Gottlieb, & England, M. 
1. (2007). Can psychiatry cross the quality chasm? Improving the quality of health 
care for mental and substance use conditions. The American Journal of 
Psychiatry, 164, 712-719. 
Poll, (2007). An overview the diagnosis, prevention, and management 
hepatitis C. Gastrointestinal Nursing, 
139 
Poll, (2009). The of the community nurse in C ..... ~bU'''JhJ and treatment. 
British Journal of Community Nursing, 292-296. 
Pozza, R. (2008). Clinical UL"'''~M,''''L of HIV /hepatitis C Journal of 
the American Academy of Nurse Practitioners, 20,496-505. 
Pradhan, M. M., Horwell, R., Jones, Ramsey, J. L., & Cassidy, W. (2005). Evaluation 
of the federal of for which h",,..,,<>t1t,,,,_r 
infected Hill."".'" are considered for treatment. Digestive Disease and Sciences, 
50, 714-718 
Quelhas, R., 
C 
Lopes, (2009). problems patients m!l~ctt:d with 
and during antiviral treatment with interferon-alpha: review. Journal 
of Psychiatric Practice, 262-281. 
D.B., B. Wittenborn, B., Roblin, D.W., 
Patel, N., Ward, J. W., & Weinbaum, (201 The cost-effectiveness of 
birth- cohort screening for hepatitis C antibody in U.S. primary care settings. 
American Journal of Physicians, 156, 
Rifai, M. A, Moles, 1. K., Short, D. (2006). 
outcomes am~[)mr patients with psychiatric 
Rural Assistance Center (2012). "'TM"'''~'f'I from 
http://www.raconline.org/states/michigan.php 
Santos, S. A, Kontorinis, N., & Dieterich, D. (2005). 
C treatment eligibility and 
Psychiatric Services, 
M,mage!nelntofv.~v .. "v 
hepatitis C patients with HIV. Liver Disease, 8,433-441. 
140 
Schackman, B. P. Weitzman, Mushlin, A. Jacobson, 1. 
(2008). Quality-of-life for ""'~'<>T',"" C treatment: Do 
providers Medical Decision Making, 233-242. 
Shehab, T. M., Sonnad, Gebremariam, A., Schoenfeld, P. (2002). Knowledge of 
hepatitis C management by internal medicine residents: Trends 
over 2 The American Journal of Gastroenterology, 97, 
Shehab, T. M., Sonnad, S. S., Lok, S. (2001). Management of hepatitis C patients 
primary care physicians the USA: ofa <011T'''''''' Journal 
Viral Hepatitis, 8, 
Shutt, J. Robathan, J., Vyas, (2008). ofa nurse I.r"'v ......... " on 
the treatment chronic hepatitis British Journal of Nursing, 17, 
Silverman, c., A. & Freudenreich, O. (2010). Interferon-induced psychosis as 
a psychiatric contraindication to hepatitis C treatment: A and 
discussion. Psychosomanics, 1-7. 
A., (2003). A for hepatitis 
C services into an HIV I AIDS ..--r{'H'f,..,"..... Journal of the Association in 
AIDS Care, 14, 95-1 
Strinko, J. M., Di A., & Hoffmann, J. A. (2004). descriptive study of the 
relationship between mood disorders and hepatitis C treatment compliance: Does 
playa role? Issues in Mental Nursing, 71 
141 
'UP"Trp D. (2007). Integrating services for users: A model to 
engagement and outcomes. International Journal of Drug Policy, 18, 
410. 
Tait, 1. M., McIntyre, McLeod, Nathwani, & Dillon, 1. (2010). The 
impact of a naIllag€~O care nprlUA,'V on attendance, follow-up, and treatment at a 
hepatitis e specialist centre. Journal of Viral Hepatitis, 17, 698-704. 
U.S. Department of Health Human (201 The patient protection and 
affordable care act. Retrieved from !!.!±,IL:!..::...!.!...:!.!...!.!~~~~~:..!L!~~!.!.!:!l~. 
(2004). Retrieved from 
http://www.uspreventiveservicestaskforce.org/uspst£luspshepc.htm 
Thiel, D. H., Anantharaju, & S. (2003). to treatment 
e in with recent history intravenous drug 
Journal of Gastroenterology, 98, 
Zandt, S. E., '--' ...... VA.'-. M. & Kelley, 
-2288. 
(2002). community-based 
American 
clinic's approach to mana:gernellt problems the uninsured: The 
hepatitis e example. Family & Community Health, 61-70. 
",t",.·"",,, Health Administration (2010). Retrieved from 
http://www.hepatitis.va.gov/patientlfaqslhow-common-is-hepatitis.asp 
Weiss, 1., S. (2009). Psychiatric manajd:t:ITllt:nL HIV /HeV cO-lntelc:ted 
patients beginning treatment e infection: Survey of provider 
practices. General Hospital Psychiatry, 31, 
142 
Wilkins, Malcolm, J K., """,eu«. D., Schade, R. R (2010). Diagnosis 
and treatment. American Family Physician, 81, 1351 
Wise, M., Bialek, S., Bell, 
hepatitis C-related mortality 
47, 1128-1135. 
& Sorvillo, 
the United 
(2008). Changing trends in 
1995-2004. Hepat%gy, 
World Health Organization. (2012). Retrieved from 
http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/enlindex4.html 
Wong, J. B., McQuillan, M., McHutchison, J. & Poynard, T., (2000). 
future hepatitis c morbidity, mortality, and cost 
Journal of Public Health, 90, 1562-1569. 
United American 
Woods, A. R, Herrera, 1. (2002). Hepatitis Latest treatment guidelines. 
Consultant, 42, 
Yawn, P., ""'""_"''-'. L. & Wollan, P. (2008). 10-year trends in diagnosis and 
treatment of hepatitis C and concomitant mental health disorders: 1995-2005. The 
Primary Care Companion to the Journal of Clinical Psychology, 10,349-354. 
Yovtcheva, S. M., IV"'l..., .... J & Van Linden, J. (2005). Psychiatric 
comorbidities among hepatitis patients. from 
http://focus. psychiatryonline.org/ datalJ ournalslFOCUS/261 . pdf 
Zickmund, S. L., C. L., Blasiole, 1. A., Shinkunas, LaBrecque, & 
Arnold, R M. (2006). Majority of patients with hepatitis C express physical, 
mental, difficulties with antiviral treatment. European Journal of 
Gastroenterology & Hepatology, 18, 381-388. 
143 
Zickmund, E. Masahiro, M., Ippolito, L., & R. (2003). 
They treated me like a leper: Stigmatization and quality of of patients with 
,,'"'''"'', ........ , C. Journal of General Internal Medicine, 18,835-843. 
144 
